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Liver performs a multitude of functions ranging from detoxification, metabolism and 
digestion. To execute these tasks, one of the mechanisms that the liver utilizes is nuclear receptor 
signaling, which in turn can transcriptionally regulate gene networks. My doctoral thesis focuses 
on studying the role of two nuclear receptors, FXR and SHP in maintaining liver function. 
Farnesoid X Receptor (FXR) and Small Heterodimer Partner (SHP) are well-known regulators of 
glucose, fat and bile acid homeostasis. Here, I uncover novel roles for FXR-SHP axis not only in 
the liver but also in extrahepatic organs, like heart. In Chapter 2, I discuss how hepatic loss of 
FXR and SHP results in increased glycosylation of liver proteins and structural defects in Golgi 
apparatus, and ultimately liver cancer.  Chapter 3 focuses on comprehending how FXR-SHP 
ablation results in increased drug metabolic capacity of the liver. Finally, chapter 4 discusses 
how liver dysfunction, caused by loss of FXR and SHP, can induce metabolic and functional 
defects in heart. Taken together, these projects will help understand some of the FXR and SHP 
transcriptional networks under different physiological and pathological contexts and may open 
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CHAPTER ONE: ROLE OF NUCLEAR RECEPTOR SIGNALING IN MAINTAINING 
LIVER FUNCTIONS 
1.1. Liver Physiology and Function 
Liver is the largest internal organ located below the diaphragm in the upper right 
quadrant in the abdomen. Histologically, a liver lobule is composed of two major types of cells: 
parenchymal hepatocytes and non-parenchymal cells including cholangiocytes, sinusoidal cells, 
stellate cells and Kupffer cells1–3. Epithelial hepatocytes constitute 70-80% of the liver volume 
and perform majority of the liver functions3,4. Cholangiocytes are epithelial cells lining bile ducts 
in the liver that modify bile composition by secretory and reabsorbative processes5,6. Sinusoidal 
cells are endocytic in nature and extract oxygen and nutrients from the blood to nourish the 
hepatocytes7,8. Stellate cells produce collagen, therefore are crucial for matrix formation during 
liver development, but their activation during liver fibrosis causes scarring of the tissue9,10. 
Kupffer cells, on the other hand are resident hepatic macrophages11,12. Taken together, non-
parenchymal cells along with hepatocytes play a key role in maintaining liver function2,4,13.  
The liver orchestrates about 500 functions, individually as well as in coordination with 
other organs. These functions include but are not limited to detoxification, glucose and lipid 
homeostasis, and digestion. These liver functions are achieved by multiple mechanisms 
including hormone-dependent nuclear receptor signaling.  
 
1.2. The Nuclear Receptor Superfamily 
Nuclear receptors belong to the superfamily of transcription factors that are activated by 
small lipophilic molecules14,15, which diffuse across the membrane to regulate a wide array of 
physiological functions including growth, development, reproduction and metabolism15–17. 48 
human genes are known to encode for nuclear receptors till date. Nuclear receptors are either 
sequestered in the cytoplasm (Type I) or localized in the nucleus (Type II). Upon ligand binding, 
Type I receptor is translocated to the nucleus to regulate target gene expression. An example of 
Type I receptor is Constitutive Androstane Receptor that is retained in the cytoplasm when 
inactive. Upon activation by drugs, it enters the nucleus, heterodimerizes with Retinoid X 
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Receptor (RXR) and triggers detoxification transcriptional machinery18,19. Type II receptors, in 
the absence of a ligand, are complexed with corepressor proteins. Ligand binding results in 
dissociation from the corepressor complex and association with coactivator proteins. Bile acid 
receptor Farnesoid X Receptor is an example of Type II nuclear receptor. When bile acid binds, 
it is recruited to its response element, along with RXR to regulate transcription20,21.  
Another classification is based on the type of ligand bound: (1) Endocrine Receptors, (2) 
Orphan Receptors and (3) Adopted Orphan Receptors. Endocrine receptors display strong 
affinity towards hormones, a few examples being Estrogen Receptor, Vitamin D Receptor and 
Glucocorticoid Receptor22–24. They were identified on the basis of their physiological function. 
Whereas in case of orphan receptors, the gene sequence was identified first, followed by 
screening chemical libraries for ligands and using gain and/or loss of function approaches to 
determine their physiological role. Upon ligand identification and characterization, these 
receptors are classified as adopted orphan receptors25,26. For example, Constitutive Androstane 
Receptor27, Farnesoid X Receptor28 and Liver X Receptor29 were first identified via yeast two 
hybrid screening and later were fully characterized for ligand binding and function. These 
adopted receptors show weaker affinity towards their ligands- dietary lipids and ingested 
chemicals. However, the ligands for orphan nuclear receptors like Small Heterodimer Partner30, 
Liver Receptor Homolog 131, Hepatocyte Nuclear Factor 432 are still unknown.   
 
Structural Domains of Nuclear Receptors and their Functions 
Nuclear receptor contains these six domains: N-terminal A/B domain, DNA binding 
domain (DBD), Hinge region (D), Ligand binding domain (LBD) and C-terminal domain 
(F)16,33,34. DBD, being the highly conserved domain among all nuclear receptors, is utilized to 
identify new orphan receptors by screening cDNA libraries. The C-terminal domain may or may 
not be present in a nuclear receptor. 
  
(1) N-terminal A/B domain 
  The N-terminal is the least conserved domain in size and sequence amongst all nuclear 
receptors. This variation accounts for differential recruitment on the response elements, wide-
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ranging affinities for transcription initiation complexes, distinct transcriptional abilities and 
diverse functions. This domain harbors an activation function region called AF-1 which is crucial 
for transactivation in a ligand-independent manner. Mutational analyses demonstrate the 
importance of alpha-helical structures as well as hydrophobic residues in AF-1 domain in 
mediating gene activation35–37. Upon interaction with transcriptional coregulators, AF-1 residues 
undergo a functionally active conformational change and demonstrate increased hydrophobic 
binding with the partner protein, resulting in a stronger transcriptional capacity. Some of these 
coactivators include CREB binding protein (CBP), histone acetyltransferases (HAT) whereas, 
nuclear receptor corepressors (NCoR), histone deacetylases (HDAC) are a few key corepressors 
that are known to interact with nuclear receptors38–40. 
 Function of a nuclear receptor can be regulated by modifications at AF-1 domain. One of 
the most common post translational modifications is phosphorylation of key residues in the N-
terminal region. Phosphorylation may affect folding in this domain and influence its interaction 
with transcriptional machinery. For example, phosphorylation in the N-terminal of 
Glucocorticoid receptor and Estrogen receptor induces a stable tertiary structure in the domain, 
allowing for stronger binding with coactivators41,42. Another commonly observed modification is 
SUMOylation in which a Small Ubiquitin-like Modifier (SUMO) protein is covalently tagged to 
the protein of interest. N-terminal SUMOylation of Androgen receptor results in transrepression 
of their target genes. Whereas, SUMOylation in AF-1 domain of PPARγ activates gene 
transcription43,44. Nuclear Receptors can also be glycosylated at the AF-1 regions. Farnesoid X 
receptor (FXR) harbors an O-glycosylation site within its AF-1 domain which inhibits its 
transcriptional activity45. Thus, AF-1 domain is critical for nuclear receptor function. 
 
(2) DNA Binding Domain (DBD) 
  The most conserved domain within the nuclear receptor superfamily, DBD is essential for 
receptor interactions with DNA. This highly structured domain is composed of two zinc-finger 
motifs, each containing four conserved cysteine residues that tetrahedrally bind the zinc atoms 
via coordinate bonds. These motifs form a compact globular domain consisting of two 
perpendicular tertiary alpha helices and a short beta sheet46–48. The helix in the N-terminal motif 
contains a three-amino acid sequence called P-box that is required for DNA binding specificity. 
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These amino acids can either be Gly-Ser-Val or Glu-Gly-Ala. NMR and X-ray crystallographic 
studies indicate that Glu and Val directly bind to the DNA sites called hormone response 
elements. These sites are variable in location such that they can be present upstream or 
downstream the coding sequence, within the promoter, or within the intronic regions but they are 
specific to the nuclear receptor49–51. A typical response element is the hexameric nucleotide 
sequence AGGTCA or its possible variations arranged in form of direct (AGGTCA {n}x 
AGGTCA), inverted (AGGTCA {n}x TGACCT) or everted (TGACCT {n}x AGGTCA) repeats. For 
example, the most common response element for Farnesoid X Receptor is AGGTCA n TGACCT 
(IR1: inverted repeats separated by one nucleotide), while for Constitutive Androstane Receptor 
is AGTTCA nx AGTTCA (DR3/4/5: direct repeats separated by three/four/five nucleotides)
52–54.  
 Nuclear receptors either homodimerize (like Estrogen Receptor, Glucocorticoid 
Receptor) or heterodimerize with RXR (including Farnesoid X Receptor, Constitutive 
Androstane Receptor) and bind their respective response elements. This dimerization is 
controlled by a five-amino acid loop (Ala-Gly-Arg-Asn-Asp) called D-box present in the second 
zinc finger motif. The amino acids in D-box provide a strong interface for homodimerization. 
However, it does not contribute to DNA binding specificity55,56. Interaction of the receptor dimer 
with DNA initiates distortion of the minor groove resulting in a conformational change in the 
DNA double helix. This allows for sequence recognition by the N-terminal zinc-finger motif57,58. 
Then, coactivators are recruited to the DNA. These coactivators possess histone acetylation 
activity, which neutralizes the positive charges on histones. This disrupts the histone-DNA 
interactions enabling nuclear receptors to be recruited to their response elements. Previous 
studies have shown that recruitment of nuclear receptor to naked DNA can promote transcription 
in vitro. However, addition of corepressors inhibits their transcriptional activity59–61. 
 Post translational modifications of DBD have shown to regulate nuclear retention, 
dimerization, coregulator interactions and transcriptional activity. DBD phosphorylation in 
nuclear receptors like HNF4α impairs its nuclear transport and prevent DNA recognition62. On 
the contrary, phosphomimetic mutants of Ser residue in FXR DBD reduces ligand dependent 
FXR transactivation as well as its interaction with coactivator PGC1α63. Another common 




(3) Hinge Region 
  Also known as the C terminal extension of DBD domain (CTE), this region is flexible in 
nature and has multiple functions. First, it harbors a nuclear localization signal which regulates 
subcellular localization of the receptor. Second, mutational analysis studies have shown that the 
hinge domain can result in reduced interaction with coactivators. ER hinge region favors its 
nuclear transport and binding with coactivators like c-Jun65,66. Third, hinge domain has a role in 
DNA binding affinity. Alternative splice variants affecting hinge domain in FXR exhibit 
different DNA recognition67. Finally, the length of the hinge domain has also shown to be an 
important factor controlling receptor function. Deletion of five amino acids at the C terminal 
hinge region in Vitamin D Receptor suppresses its transcriptional ability. However, this defect is 
rescued upon inserting alanine residues to keep the length intact indicating that a section of hinge 
region could have sequence-independent functions68. 
Like other domains, the hinge region also undergoes extensive post translational 
modifications to control its activity. Phosphorylation of Ser residue in RARα hinge region 
prevent receptor dimerization69. However, phosphorylation in PPARα has the opposite effect70. 
SUMOylation of conserved Lys residues within ERα hinge domain favors transactivation but 
does not affect its localization71. In contrast, PPARα SUMOylation increases corepressor NCoR 
binding, thus generating a defective receptor72. 
 
(4) Ligand Binding Domain (LBD) 
  This domain not only provides a site for binding a lipophilic molecule but also presents 
an interface for dimerization as well as coregulator interactions. LBD acts as a “molecular 
bridge” connecting a chemical signal (hormone) to a biological response (transcription). Upon 
ligand binding, the receptor undergoes a conformational switch to act as either a transactivator or 
a transrepressor. X-ray diffraction studies demonstrate presence of 12 alpha helices organized in 
a three layer, antiparallel sandwich33,73,74. Amino acids in helix 3,5 and 10/11 are involved in 
ligand binding. Various factors like hydrophobic interactions, steric hindrance and LBD shape 
and size regulate the specificity and affinity of ligand-receptor binding. Structural differences in 
LBD are observed in receptor isoforms that result in altered coregulator binding33,73,74.  
6 
 
  Unliganded LBD is in an open conformation. Upon cognate ligand binding, the receptor 
undergoes dramatic rearrangement in helices 3,4,5 and 12 to form a hydrophobic cavity that 
stabilizes ligand interaction. Moreover, this compact structure recognizes and binds to the 
LXXLL motif on most nuclear coactivators. This interaction is stabilized not only by 
hydrophobic bonds between coactivator leucine residues and LBD hydrophobic pocket but also 
by a charge clamp formed by hydrogen bonds between lysine of helix 3 and glutamate of helix 
12 and peptides of the LXXLL domain75–77. Repositioning of helix 12, also known as the 
Activation function domain AF2, is critical for docking of LXXLL coactivator and formation of 
the charge clamp. Importantly, even slight differences in ligand structure can be detected by the 
LBD which can in turn affect coactivator recognition. Antagonist binding can position helix 12 
in a way that sterically hinders interaction with LXXLL motif, resulting in no transactivation78–
80. Further, helices 7, 9, 10 and 11 along with the loops L8-9 and L9-10 provide an interface for 
dimerization. However, ligand dependent modulation of this interface has not been observed81–83. 
  LBD is a well-known target of post translational modifications, one of the most common 
one being SUMOylation and phosphorylation. PPARγ SUMOylation promote their docking to 
NcoR corepressor complex84. SUMOylation of FXR LBD induces anti-inflammatory 
transcriptional pathway85, whereas phosphorylation has quite the opposite effect. PKCzeta 
dependent FXR phosphorylation drives its nuclear localization, followed by transactivation86. 
 
(5) C-terminal domain 
 The C-terminal domain (also known as F domain) is highly variable. Some nuclear 
receptors like Glucocorticoid Receptor and Thyroid Receptor even lack this domain. In others, 
the domain length can be up to 80 amino acids. To date, very little is known about the structure 
and function of this domain. The amino acid sequence of this domain in ERα predicts presence 
of an alpha helix separated from a beta strand by a random coiled stretch. F domain of ER 
induces hormone binding and recruitment of coactivators, thereby enhancing transcription87–89.  
The known post translational modifications within this domain include phosphorylation 
and O-GlucNAcation. F domain in ER can be modified by either of these decorations and may 
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result in opposite effects. ER phosphorylation regulates its basal functional ability. O-
GlucNAcation blocks ER binding to its response element thereby reducing its transactivation90. 
 
1.3. Nuclear receptor functions in the liver 
  The liver plays an important role in metabolism, detoxification and digestion. Several of 
these hepatic functions are tightly regulated by hormone-dependent nuclear receptor 
signaling15,34,91. The key nuclear receptors relevant to my doctoral thesis are elaborated below: 
 
 Role for Farnesoid X Receptor and Small Heterodimer Partner in Bile Acid Signaling 
One of the salient functions of hepatocytes is secretion of bile, which is a yellowish-green 
liquid containing bile acids, bilirubin, phospholipids (cholesterol, phosphatidylcholine, fatty 
acids) and inorganic salts (sodium, potassium, biocarbonate)92. Perivenous hepatocytes 
synthesize amphiphilic bile acid molecules from hydrophobic cholesterol via cytochrome P450s. 
The rate limiting step of hydroxylation at 7th carbon of the cholesterol steroid backbone occurs in 
the endoplasmic reticulum. It is catalyzed by cholesterol 7α-hydroxylase (CYP7A1), followed by 
further modifications to the steroid ring to yield chenodeoxycholic acid, a primary bile acid. 
However, when this classical pathway is abrupted, alternative pathway steps up to meet the bile 
acid demand. Alternative pathway begins with hydroxylation at 27th carbon by a mitochondrial 
sterol 27α-hydroxylase (CYP27A1). The product 27α-hydroxycholesterol is then converted into 
7α-hydroxysterol by the action of 25-hydroxycholesterol 7α-hydroxylase (CYP7B1) in 
endoplasmic reticulum, ultimately producing chenodeoxycholic acid. The intermediates from 
both the pathways can further be hydroxylated by CYP8B1 to produce a more hydrophilic 
primary bile acid called cholic acid. When secreted into the intestinal lumen, gut flora 
dehydroxylates chenodeoxycholic acid and cholic acid to produce more hydrophobic secondary 
bile acids: lithocholic acid and deoxycholic acid respectively. Finally, most of these bile acids 
are conjugated with glycine or taurine to improve their hydrophilicity for secretion. The bile 
acid-rich bile is then drained into the canaliculi via transporters like Bile salt export pump 
(BSEP) from where it enters the bile duct and stored in the gall bladder93–95.  
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Upon food cue, dietary fat in the duodenum induces secretion of the enteric hormone 
cholecystokinin which stimulates gall bladder contraction. This results in the release of bile acids 
into the duodenum. Being amphiphilic in nature, bile acids form micelles and activate lipases to 
digest lipids and promote its absorption across the intestinal brush border membrane. After fat is 
digested, 95% of bile acids is recycled back to the liver via apical sodium bile acid transporter 
(ASBT) located on the apical side of enterocytes. Bile acids are then taken up by the pericentral 
hepatocytes through Na+- Taurocholate cotransporter peptide (NTCP). In this way, only 5% bile 
acids are lost in the feces which are replenished by de novo synthesis in the liver96–99. 
Nuclear receptors Farnesoid X Receptor (FXR) and Small Heterodimer Partner (SHP) are 
key players in maintaining bile acid homeostasis. When in excess, bile acids negatively 
autoregulate their synthesis by activating FXR. Bile acid binding to the nuclear FXR results in its 
heterodimerization with RXR, docking to its response element containing IR-1 repeats of 
GAGTTAnTGACCT, leading to Shp transactivation. SHP then act as a corepressor to the nuclear 
receptors HNF4α and LRH-1 to shut off transcription of Cyp7A1 in the liver100–103 (Figure 1.1). 
Additionally, activation of intestinal FXR by bile acids promote ileal transcription of Fibroblast 
growth factor 15 (Fgf15), which is circulated to the liver. FGF15 signals via membrane receptors 
FGFR4 and β-Klotho to suppress Cyp7A1 transcription via SHP or ERK104–106. Apart from 
synthesis, FXR-SHP also coordinate bile acid transport and enterohepatic circulation by 
regulating Ntcp, Bsep, Asbt transcription107–109.  
Interestingly, global deletion of both FXR and SHP resulted in drastic bile acid 
accumulation. But, individual knockouts show only a modest increase in bile acid levels, 
suggesting a synergistic role of FXR and SHP in maintaining bile acid pools. Moreover, the 
double knockout livers display severe injury, hyperplasia and ultimately cancer 110. Therefore, it 
led us to question whether (i) disrupted BA synthesis in the liver or (ii) dysregulated BA entero-
hepatic circulation in double knockout mice is responsible for causing the liver damage. My 
thesis project is focused on delineating the contribution of liver FXR-SHP regulatory pathways 




Role of Constitutive Androstane Receptor in Detoxification 
The liver is a central hub for clearance of foreign drugs (xenobiotics). The kidneys 
excrete water-soluble substances; however, hydrophobic compounds are “biotransformed” by the 
hepatocytes prior to their excretion. An orally consumed drug enters the gastrointestinal tract 
from where it enters hepatic circulation via portal vein. The xenobiotic processing is divided into 
3 phases. Phase I involves conjugation of these drugs with reactive groups (-NH2, -COOH, -OH 
or –SH) to increase their polarity and ultimately solubility in water. These modifications occur 
by oxidation, hydroxylation, reduction, hydrolysis, cyclization upon the action of cytochrome P-
450 enzymes and NADPH. If the metabolite is sufficiently hydrophilic after this step, it may be 
excreted. Otherwise, it undergoes phase II in which the phase I products are conjugated with 
glucuronic acid, sulfate, glycine or glutathione to further increase their polarity.  These reactions 
are catalyzed by transferases including UDP-glucurosyltransferases, sulfotransferases, Glycine 
N-acyltransferases, or glutathione S-transferases respectively. These anionic tags on phase II 
metabolites are then recognized by the sinusoidal hepatic transporters like multidrug resistance 
protein and excreted in phase III of detoxification in an ATP-dependent manner111–115. 
In the liver, the NR1I subfamily of nuclear receptors regulates clearance of foreign 
compounds (xenobiotics). Constitutive Androstane Receptor (CAR, NR1I3) and Pregnane X 
Receptor (PXR, NR1I2) coordinately accomplish this function by orchestrating the 
transcriptional networks in the hepatic detoxification machinery116–119. Like a steroid receptor, 
inactive CAR is phosphorylated and sequestered in the cytoplasm by heat-shock protein 90. 
Xenobiotics can either bind directly like mouse CAR agonist TCPOBOP (1,4-Bis [2-(3,5-
dichloropyridyloxy)] benzene) or indirectly like Phenobarbital to dephosphorylate CAR and 
induce its nuclear translocation, thus activating its transcriptional potential18,120,121. Once in 
nucleus, CAR heterodimerizes with RXR, binds to DR3, DR4, DR5 recognition motifs, which in 
turn, results in increased detoxification potential of the liver.  
  Loss of FXR-SHP signaling results in cholestasis and severe liver injury. In addition, 
Fxr-Shp knockout mice exhibit induced drug metabolism capacity such that these knockouts 
mimic CAR activated mice. Here, we highlight these novel interactions between Fxr-Shp and 
CAR networks in Chapter 3.  
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Finally, Chapter 4 discusses how ablation of FXR-SHP signaling can cause cardiomyopathy 
secondary to severe liver dysfunction. In this chapter, we identify a novel mechanism by which 
bile acids may cause heart defects and highlight that reducing bile acids can be of a therapeutic 












1.4. Figure and Legend 
 





























CHAPTER TWO: A NOVEL ROLE FOR HEPATIC FXR-SHP AXIS IN REGULATING 
GLYCOSYLATION 
Mathur B1, Chen Q2, Shajahan A2, Hand NJ3, Schoonjans K4, Radar DJ3, Azadi P2 and Anakk S1 
 
1Department of Molecular and Integrative Physiology, University of Illinois at Urbana-
Champaign and 2Complex Carbohydrate Research Center, University of Georgia, 3Perelman 




Global deletion of nuclear receptor Farnesoid X Receptor (Fxr) and Small Heterodimer 
Partner (Shp) results in severe liver injury, cholestasis and ultimately hepatocellular 
carcinogenesis. However, the specific contribution of hepatic Fxr-Shp regulatory networks in 
protecting the liver against injury is not characterized. We generated liver specific Fxr-Shp 
double knockout mice (LDKO) and challenged them with a BA diet to determine their injury 
response. Within 5 days of BA diet, LDKO livers exhibited ballooning degeneration and focal 
inflammation, compared to the controls. High throughput RNA-seq revealed induction of key 
glycosyltransferases, such as Mgat5, Fut8, St3gal6 and St6gal1 in LDKO livers, which was 
corroborated by increased percentage of triantennary (complex glycans) and core-fucosylated 
glycans in LDKO livers. Interestingly, FXR or SHP individually show only a partial regulation 
of these genes, indicating their synergistic role in regulating protein glycosylation. Further, 
glycoproteomics analyses of LDKO livers revealed enrichment of proteins localized in varied 
cellular compartments like exosomes, lysosomes and endoplasmic reticulum. Since glycan 
processing and protein sorting occur in Golgi apparatus, we examined and found structural and 
functional defects in Golgi network, which is well known to cause glycosylation defects. To 
examine the mechanism underlying this defect, we measured intracellular cholesterol levels and 
found accumulation in Golgi apparatus. This may be a possible mechanism by which hepatic 





 Bile acids (BAs) are cholesterol metabolites synthesized in the liver that are responsible 
for fat digestion. When in excess, BAs can cause liver injury, cholestasis and hepatocellular 
carcinogenesis. Therefore, BA synthesis, transport and entero-hepatic recirculation needs to be 
tightly controlled. Nuclear receptors, Farnesoid X Receptor (FXR, NR1H4) and Small 
Heterodimer Partner (SHP, NR0B2) are crucial in coordinating BA balance as detailed on page 
18. Briefly, upon BA binding hepatic FXR suppresses BA synthetic gene Cyp7a1 in a SHP 
dependent manner. Additionally, intestinal FXR induces Fibroblast Growth factor (Fgf15) which 
circulates to the liver to repress Cyp7a1 via SHP and ERK pathway93,94,103–106. We have 
previously shown that global ablation of both Fxr and Shp induces spontaneous cholestasis and 
hepatotoxicity in mice110. However, the hepatic contribution of Fxr-Shp axis in protecting against 
cholestasis is unknown.  
 The liver performs a myriad of complex functions, including metabolism and 
detoxification by orchestrating various signaling networks. These dynamic networks are 
regulated not just on transcriptional and translational levels, but also by post-translational 
mechanisms. One such post-translational modification is N-Glycosylation in which a sugar 
molecule (glycan) is attached covalently to the nitrogen of asparagine (Asn) residue with a 
consensus sequence of Asn-X-Ser/Thr122,123. The key step for glycosylation initiation is 
production of Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) via Hexosamine 
Biosynthesis pathway (HBP)124–126. 2-5% of glucose that enters the cell, is directed through the 
HBP pathway, which yields UDP-GlcNAc that can be utilized for either N-glycosylation in 
endoplasmic reticulum (ER) and golgi complex or O-glycosylation (attachment of GlcNAc on 
the oxygen of Serine/Threonine) in the cytoplasm127–129.  
 In context of N-glycosylation, GlcNAc (from UDP-GlcNAc), mannose (from GDP-
Mannose) and glucose (from UDP-Glucose) are sequentially attached to a lipid oligosaccharide 
precursor, which is transported into the ER lumen by a flippase130–133. Next, the entire glycan 
precursor is transferred to Asn residues of nascent polypeptide by oligosaccharyltransferase134. 
Further processing in Golgi involves removal of mannose by mannosidases, followed by addition 
of GlcNAc by Mgat family resulting in “antennae” formation. These branched glycans are finally 
14 
 
modified by adding fucose at the glycan core by fucosyltransferase (Fut8), galactose or 
galactose-NAc via galactosyltransferases or GalNAc transferases and/or sialic acid by 
sialyltransferases (Sts). These modifications result in complex glycan structures that provide 
microheterogeneity in the cell132,135,136, and enables it to perform complex functions. 
To characterize the tissue-specific roles for FXR and SHP, we generated liver specific 
Fxr-Shp double knockout (LDKO) mice and found an unexpected role for liver FXR-SHP in 
regulating protein glycosylation. Glycan profiling analysis revealed enrichment of core-
fucosylated and triantennery structures in LDKO livers. Since Golgi dynamics are well known to 
alter protein glycosylation, we examined and observed structural and functional defects in Golgi 
apparatus in LDKO livers. Cholesterol is a key regulator of membrane fluidity and Golgi 
function137. To understand how FXR-SHP ablation results in altered Golgi dynamics, we stained 
for cholesterol and found increased depots in Golgi in LDKO livers. In conclusion, our findings 
highlight a novel function of hepatic FXR-SHP axis such that Fxr-Shp deletion modulates 
intracellular cholesterol compartmentalization, which may induce the observed Golgi 
dysfunction and increased protein glycosylation in the liver. 
 
2.3. Materials and Methods 
Animals 
Fxr-floxed and Shp-floxed mice, obtained from Dr. Kristina Schoonjans laboratory, were 
intercrossed to obtain double floxed homozygous Fxr-Shp mice (fl/fl Fxr fl/fl Shp). Further, 
these fl/fl Fxr fl/fl Shp (Control) mice were bred with mice expressing the Cre-recombinase 
under the control of Albumin promoter (AlbCre mice, Envigo/Harlan laboratories) to obtain 
liver-specific double knockouts (fl/fl Fxr fl/fl Shp AlbCre (+), LDKO). The mice were 
maintained on a C57/B6 background and housed on a standard 12-hour-light/dark cycle. All the 
experiments were carried out on 10-12 weeks old male mice as outlined in the Guide for the Care 
and Use of Laboratory Animals, the National Academy of Sciences (NIH publication 86-23, 
revised 1985) and approved by the Institutional Animal Care and Use Committee at University 
of Illinois at Urbana-Champaign. To study how LDKO mice respond to BA-induced stress, we 
fed 10-11 weeks old LDKO and control mice with normal chow or 1% Cholic Acid (CA) diet for 
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5 days. The mice were fasted 7-9 hours prior to collecting serum, liver, gall bladder and Ileum 
(n=6-12 mice per group).  
 
Chemicals 
 MethylCellulose was obtained from Sigma (Catalog #0262) and GW4064 from Cayman 
Chemicals. Fasted C57B6 mice (Envigo/Harlan laboratories) were gavaged with either Vehicle 
(1% MethylCellulose 1% TritonX-100 in PBS) or 50mg/kg FXR agonist GW4064. Mice were 
gavaged twice, first in the evening, second in the morning and sacrificed 3 hours post second 
gavage (n=5 mice per group). Primary hepatocytes isolated from C57B6 mice were incubated 
with 100 µM of DCA (Sigma-Aldrich) for 6 hours (n=2 mice per group, 3 technical replicates). 
 
Genotyping 
 Mouse tails were clipped during weaning to obtain genomic DNA. Tails were lysed using 
DirectPCR tail lysis buffer (Viagen Biotech) and proteinase K by an overnight incubation at 55 
°C. Proteinase K was heat inactivated for 1-2 hours and PCR was performed on the DNA 
isolated using primers listed in Supplementary Table 2.1. 
  
Serum Biochemistry 
Blood was collected and centrifuged at 7000-8000xg for 10 minutes. The serums 
collected were tested for ALT and AST enzymes using Infinity ALT/GPT and AST/GOT kits 
(Thermo Scientific). Serum BA levels were measured using a colorimetric BA assay kit 
(Genway) according to the manufacturer’s protocol. Fresh serum from controls and LDKO mice 
(n=5-6 mice per group) was analyzed for lipid metabolites using FPLC at Perelman School of 






Tissue BA Assay 
For hepatic and intestinal BA analysis, about 100 mg of liver tissue or whole ileum was 
homogenized in 75% ethanol, followed by a 2-hour incubation at 50°C and centrifugation at 
15000xg for 10 minutes. The supernatant was diluted with 1x PBS and used to measure BA 
content in the liver or intestine respectively using the colorimetric BA assay kit mentioned 
above. The BA levels were normalized to the weight of the tissue used. For biliary BA 
measurements, intact gall bladders from mice were punctured to obtain the content, which was 
further diluted with 1x PBS and analyzed for BA pools. 
 
Histology 
Liver tissues from all the mouse cohorts were fixed in 10% neutral-buffered formalin 
overnight, subsequently dehydrated in increasing concentrations of ethanol (70-100%), xylene 
and finally embedded in paraffin. 5 µm thick liver sections were cut, deparaffinized and stained 
with hematoxylin and eosin (H&E) using standard histological protocols. These sections were 
also stained with periodic acid and Schiff’s reagent for PAS staining. Briefly, the deparaffinized 
sections were stained with 0.5% periodic acid for 10 minutes, followed by wash in water and 
incubation in Schiff’s solution for 30 minutes. Next, slides are rinsed in 0.55% Potassium 
Metabisulfite for 30 seconds and washed in running warm tap water for 10 minutes to develop 
the pink color. Finally, the sections were counterstained with Hematoxylin, mounted and imaged. 
 
Quantitative real time PCR (qRT-PCR) Analysis 
RNA was isolated from snap frozen livers (n=4-5 per group) using TRIzol (Invitrogen) 
and reverse-transcribed for gene expression analysis by SYBR® Green™ based quantitative real 
time reverse transcription polymerase chain reaction (qRT-PCR) using mouse specific primer 
sets, listed in Supplementary Table 2.2. Relative gene expression was calculated by delta- delta 






 RNA was isolated from Control and LDKO livers (n=3 per group) using RNeasy tissue 
mini-kit (Qiagen). RNA quality was tested using an Agilent bioanalyzer by the Functional 
Genomics Core at the Roy J. Carver Biotechnology Center, UIUC. Hi-Seq libraries were 
prepared, and 100 bp paired end Illumina sequencing was performed on a HiSeq 4000 at the 
High Throughput Sequencing and Genotyping Unit, UIUC. Reads were processed for quality 
using Trimmomatic138 and aligned to the mouse genome (mm10) using STAR139. Gene 
expression was determined as Fragments per kilobase million (FPKM) using count and 
differential expression values obtained from DESeq2140 and HTseq141. Fold change of >1.5 and 
<0.67 was considered significant. Gene ontology pathway and cellular component analysis was 
performed using DAVID and mapped using Enrichment maps plugin in Cytoscape. Mouse 
reference gene set served as background.   
 
Extraction of Proteins from Mouse Liver for Glycan Profiling, Glycoproteomics and Proteomics 
 Control and LDKO mice (n=5 mice per group) liver tissues were tested for glycan 
structural diversity in glycoproteins using MALDI-TOF142 and Mass Spectrometry at Complex 
Carbohydrate Research Center, University of Georgia. Briefly, about 100 mg liver tissue was 
homogenized in 1 ml of ice-cold methanol/water (1:1 volume ratio) using a micro-homogenizer. 
Chloroform:methanol:water at the ratio of 4:8:3 was added, mixed vigorously and left to 
incubate at room temperature (about 20 oC) for approximately 2 h on a bench rocker. The sample 
was then centrifuged at 4 oC, 3000 rpm for 15 min to separate the precipitated tissue proteins 
from the supernatant glycolipids layer. The chloroform:methanol:water extraction was repeated 
two more times. The protein pellet was blown for a few minutes under a stream of nitrogen just 
to remove the excess chloroform/methanol while preventing complete drying. Next, 1 ml of ice-
cold water and 4 ml of ice-cold acetone were added to the sample for acetone precipitation and 
stored at -20 oC. After about 4 h, the sample was centrifuged at 4 oC, 3000 rpm for 15 min and 
the supernatant was discarded. Acetone precipitation was repeated one more time and finally, the 
pellets were processed using only 4 ml of ice-cold acetone, following the same procedure. The 




About 5 mg of protein pellet was resuspended in 50 mM ammonium bicarbonate buffer 
and digested with 100 µg trypsin for 24 h at 37 oC, followed by purification by passing through a 
C18 solid phase cartridge after inactivating trypsin by heating at 95 oC for 5 min. The eluted 
peptides were treated with two aliquots of 4 µL PNGaseF (second aliquot after 7 h) in 300 µL 
reaction buffer for a total incubation time of 18 h. The released N-glycans were separated from 
the peptides by passing through a C18 solid phase cartridge and were dried by lyophilization. 
The eluted N-glycans were permethylated by adding 350 µL of NaOH/DMSO base and 100 µL 
of methyl iodide and incubating for 10 min at room temperature with shaking. The 
permethylation reaction was quenched by adding 1 mL of water and the permethylated glycans 
were extracted by 2 mL of dichloromethane. The extracted glycans in dichloromethane were 
dried under a stream of nitrogen and analyzed by MALDI-MS by using DHB as the matrix. 
 
Glycoproteomics Analysis 
About 1 mg of proteins extracted from the control and knockout liver tissues was 
dissolved in 300 µL of 50 mM ammonium bicarbonate buffer. 130 µL of dithiothreitol (DTT) 
solution (17 mg/mL) was added to the samples and incubated at 37 ºC for 90 min. Subsequently, 
130 µL of iodoacetamide (IAA) solution (65 mg/mL) was added to the sample for 
carbamidomethylation and incubated at room temperature for 90 min in dark. The sample was 
dialyzed against double distilled water and lyophilized. Further, the liver tissue proteins were 
digested by adding sequencing-grade trypsin (Promega, 0.4 µg/µL) at a trypsin to protein ratio of 
1/40 and incubated at 37 ºC for 12 h. The digestion was terminated by heating at 95 ºC for 5 min, 
desalted by C18 solid phase extraction cartridges and then were dried under speed vacuum. The 
peptides and glycopeptides were subsequently re-dissolved in 0.1% formic acid in water. The 
digests were enriched for the glycopeptides by using ProteoExtract® Glycopeptide Enrichment 
kit (Millipore, MA) and stored at - 30 ºC until analysis by nano-LC-MS/MS. 
Desalted liver protein digests were analyzed on an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Fisher Scientific, MA) equipped with a nanospray ion source and 
connected to a Dionex binary solvent system. Pre-packed nano-LC columns of 15 cm length with 
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75 µm internal diameter (id), filled with 3 µm C18 material were used for chromatographic 
separation of digests. Precursor ion scan was performed at 120000 resolution in an Orbitrap 
analyzer, precursors at a time frame of 3 secs were selected for subsequent fragmentation using 
HCD at a normalized collision energy of 28 and CID at a normalized collision energy of 40. The 
threshold for triggering an MS/MS event was set to 500 counts. The fragment ions were analyzed 
on Orbitrap after HCD and CID fragmentation at a resolution of 30000. Charge state screening 
was enabled, and precursors with unknown charge state or a charge state of + 1 were excluded 
(positive ion mode). Dynamic exclusion was enabled with an exclusion duration of 30 secs. 
The LC-MS/MS spectra of the tryptic digest of proteins were searched against mouse 
protein database in.fasta format (downloaded from uniport) using Byonic 2.3 software with 
trypsin as the digestion enzyme. Carbamidomethylation of cysteine and oxidation of methionine 
were selected as variable modifications. Common mammalian N-glycans were used as variable 
modifications on asparagines. The LC-MS/MS spectra were analyzed manually for the 
glycopeptide fragmentation on HCD and CID with the support of Xcalibur 3.0.63 software. The 
spectra of glycopeptides were evaluated for the glycan neutral loss pattern, oxonium ions and the 
glycopeptide fragmentations and identified the glycans. For the relative ratio calculation, the 
peak area of the glycoforms were extracted manually using the Xcalibur 3.0.63 software. 
Unannotated glycopeptides were identified based on the presence of oxonium ions, and neutral 
losses on the spectra of glycopeptides. 
 
Proteomics Analysis 
The raw data were processed using the MaxQuant software (version 1.6.2.3 Jürgen Cox, 
Max Planck Institute of Biochemistry, Martinsried, Germany) with the built-in search engine 
Andromeda. Protein sequences database of mouse proteome in.fasta downloaded from Uniprot 
(June 2018) was used. Carbamidomethylation of cysteines was set as fixed modification and 
protein N-terminal acetylation and oxidation of methionines was set as variable modification for 
the peptide search. A mass tolerance of 4.5 ppm was allowed for precursor search and 20 ppm 
mass accuracy were set as a tolerance for fragment identification. Up to two missed cleavages 
were allowed for trypsin digestion. The options of label-free quantitation (LFQ) and “Match 
between runs” was enabled and features within a time window of 0.7 min were used to match 
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between runs. Normalization was performed by built-in algorithm of MaxQuant. Both unique 
and razor peptides were used for LFQ and the false discovery rates (FDR) for the identifications 
were set to 1%. The LFQ intensities obtained through MaxQuant were filtered and statistically 
analyzed using the Perseus software (version 1.6.1.3 Jürgen Cox, Max Planck Institute of 
Biochemistry, Martinsried, Germany). Protein groups detected only by peptides with modified 
sites, contaminant matches and matches to the reverse database were removed. The LFQ 
intensities were transformed by log2(x) option and the missing LFQ intensity values (NaN) for 
non-detected protein groups were replaced using low LFQ intensity values from the normal 
distribution (width = 0.3, down shift = 1.8).  
 
Cholesterol-Filipin Staining 
Frozen liver sections from control and LDKO mice (10) were fixed in 4% PFA for 10-
15 minutes at room temperature and incubated overnight at 4°C with 200 g/ml Filipin (Sigma) 
in dark. These sections then stained with NucRed for probing for nucleus for 15-20 minutes and 
mounted using aqueous cc mounting media. Filipin staining was imaged using confocal 
microscope LSM 710 using 405 nm laser and a green psuedocolor was assigned to it.  
 
Transmission Electron Microscopy 
 1 mm thick liver sections were fixed in 2.5% Glutaraldehyde (pH =7) for 2-3 hours, 
followed by post-fixation with 1% Osmium tetroxide (OsO4) in 0.1 M Cacodylate buffer for 60 
minutes. These sections are then dehydrated through ethanol series and embedded using epoxy 
resin. Ultra-thin sections are cut and left to dry, followed by imaging using transmission electron 
microscopy. 
 
Fasting Serum Glucose measurements 
Control and LDKO mice were fasted for 12 hours and blood glucose was measured by 





 1-way ANOVA with post-hoc Bonferroni test was used for comparison of multiple 




Characterization of liver-specific Fxr-Shp double knockout mice 
We have previously shown that global deletion of both Fxr and Shp (DKO) results in 
liver injury (Figure 2.1A) and juvenile cholestasis110 (Figure 2.1B), and ultimately hepatocellular 
carcinogenesis143 (Figure 2.1C). To delineate if the hepatic Fxr-Shp axis is necessary to protect 
against liver injury, we generated liver specific Fxr-Shp double knockout (LDKO) mice (Figure 
2.1D). The knockouts were verified by genotyping and qRT-PCR assays (Supplementary Figure 
2.1A, B). To examine their response to BA overload, both Control and LDKO mice were fed 
CA-enriched diet for 5 days. CA feeding resulted in a modest reduction in body weight and 
increase in the hepato-somatic index in LDKO mice (LDKO+CA) compared to Control+CA 
mice (Supplementary Figure 2.1C). However, gross liver pictures showed no significant 
difference between the mouse cohorts (Supplementary Figure 2.1D). 
Histological analysis revealed focal inflammation and ballooned hepatocytes in Chow-
fed LDKO livers, which was much stronger in CA fed LDKO livers (Figure 2.2A). Next, we 
measured the circulating levels of the known markers of liver injury, hepatic enzymes ALT and 
AST. The serum levels of these enzymes were modestly elevated in Control+CA serums, 
whereas this increase was drastic in LDKO+CA serum (Figure 2.2B). In addition, LDKO+CA 
mice displayed severe cholestasis and accumulated pathological levels of BAs in the serum and 
liver (Figure 2.2C). Finally, LDKO mice spontaneously developed liver tumors at an age of 12-
14 months. However, these tumors were significantly lesser than their age-matched global 
double knockouts (Figure 2.1C, 2.2D). These findings indicate that hepatic Fxr-Shp axis 




BA homeostasis machinery is dysregulated in LDKO livers 
 Since LDKO+CA livers were cholestatic, we investigated if the genes involved in 
maintaining BA homeostasis, including synthesis, transport and metabolism were altered in 
LDKO mice 93–95. As expected, the rate limiting enzyme in the classical BA synthesis pathway 
Cyp7a1 was higher in LDKO livers and upon CA challenge, repressed in the Control livers. 
However, this CA-mediated repression was blunted when hepatic Fxr-Shp axis was lost (Figure 
2.3A). Gene expression profile for Cyp8b1, which directs BA precursors towards more CA 
production, displayed similar expression profiles as Cyp7a1 (Figure 2.3A). On the other hand, 
CA diet was able to upregulate the alternate BA synthesis pathway gene Cyp27a1 in both LDKO 
as well as Control livers. Even though Cyp7b1 levels were higher in LDKO mice, the CA-
mediated repression was maintained (Supplementary Figure 2.2A). These data are in line with 
increased BA pools observed in LDKO+CA mice. Next, we analyzed the genes involved in BA 
transport into the bile, circulation and reuptake from intestine96,97. LDKO livers showed 
suppressed expression of canalicular transporter Bsep/Abcb11, a well-known transcriptional 
target of FXR. Mdr1a/Abcb1a was downregulated in LDKO+CA livers compared to 
Control+CA (Figure 2.3B). However, no change in Mrp2 was observed within the mouse cohorts 
(Supplementary Figure 2.2B). Transporters responsible for BA efflux into circulation 
Mrp3/Abcc3 and Mrp4/Abcc4 were upregulated in Control+CA, with an even higher induction in 
LDKO+CA (Figure 2.3C). Finally, genes responsible for BA uptake into hepatocytes such as 
Ntcp were lower in LDKO livers, whereas Oatp2/4 was upregulated, with no change in Oatp1 
expression (Figure 2.3D, Supplementary Figure 2.2B). However, in response to CA diet, Oatp1 
was suppressed in both CA treated groups but Ntcp was upregulated in LDKO+CA liver, with no 
alteration in Control+CA mice. In addition, genes encoding phase I and phase II enzymes in BA 
metabolism and excretion95 were robustly upregulated in LDKO+CA mice (Figure 2.3E), 
indicating a response to BA accumulation. Taken together, this data reveals that hepatic Fxr-Shp 





LDKO mice exhibit increases in N-glycosylation pathway 
 To decipher the molecular networks that are coordinately regulated by the hepatic Fxr-
Shp, we performed RNA-seq analysis in Control and LDKO livers. We found that more than 
2600 genes were significantly altered between control and LDKO livers. Of these 2600 genes, 
1253 genes were upregulated while 865 genes were downregulated in LDKO livers (Figure 
2.4A). To further investigate these transcriptomic changes, we performed pathway analysis using 
Cytoscape (Figure 2.4B) and discovered an unexpected enrichment of genes involved in the 
glycosylation pathway. We further probed this gene set and found that these alterations were 
unique and encoded for N-linked glycoproteins, but not O-linked glycoproteins (Figure 2.4C). 
Next, we examined if this increased N-glycosylation is a result of induction in 
glycosyltransferases expression in the LDKO livers. We further analyzed the RNA-seq data and 
identified upregulation of several glycosyltransferases that are crucial for “decorating” 
glycoproteins135,144,145. For instance, Mgat5 (N-acetylglucosaminyl-transferase V) that promotes 
glycan branching, Fut8 (Alpha-1,6-fucosyltransferase) that adds fucose to the glycan core, and 
St3gal6 as well as St6gal1 (Sialyltransferases) that add sialyl groups were all induced in LDKO 
livers (Figure 2.4D). We validated upregulation of these transferases by qRT-PCR assays 
(Supplementary Figure 2.3A). 
 
Hepatic deletion of Fxr and Shp promotes glycan core-fucosylation and hyperbranching 
 Next, we performed glycan profiling on control and LDKO livers. Corroborating with our 
computational and gene expression profiles, about 2-fold increase in core-fucosylation and 
hyperbranching was observed in LDKO livers, compared to the controls (Figure 2.5A, B). 
Sialylation showed a similar increasing trend but was not statistically significant. No change in 
mannose-decorations occurred (Supplementary Figure 2.3B). These findings indicate that hepatic 
Fxr-Shp can regulate the hyperbranching and glycan complexities. To further analyze the 
proteins that are undergoing altered glycan processing, we performed glycoproteomics on control 
and LDKO liver lysates. Gene ontology DAVID analysis of the genes encoding for these 
proteins revealed their localization in extracellular exosome, ER and lysosome (Figure 2.5C). 
Figure 2.5D-E illustrates an example of the spectrum and quantification of the glycoforms of 
liver protein.  
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Most N-linked glycoproteins are involved in cell-ECM and cell-cell interactions. 
Moreover, increased glycosyltransferase activity results in increased cell adhesion146–149. 
Therefore, we investigated if cell adhesion genes were regulated upon loss of Fxr-Shp signaling. 
GO pathway analyses displayed upregulation of cell adhesion pathway in LDKO livers. Upon 
further mining of our RNA-seq data, we identified that key genes regulating cell adhesion 
pathway, including cell-cell and cell-ECM interactions, were indeed upregulated in LDKO livers 
(Supplementary Figure 2.4). This finding implies that Fxr-Shp axis may also control cell 
adhesion and signaling. 
  
FXR activation and SHP suppression can partially regulate some of these glycosyltransferases 
 Subsequently to test if FXR can regulate transcription of these glycosyltransferases, we 
performed a short-term activation of FXR signaling in WT mice (Figure 2.6A) and examined the 
expression of these glycosyltransferases. We found a modest but significant downregulation of 
Mgat5 (Figure 2.6B). However, no change in Fut8, St3gal6 and St6gal1 mRNA levels was 
observed when FXR was activated (Figure 2.6B). 
 Next, we analyzed these gene profiles in the livers of control and liver specific Shp 
knockout (LSKO) mice (Figure 2.6C) and found upregulation of St3gal6 and St6gal1 only 
(Figure 2.6D).  These findings indicate that Fxr and Shp signaling individually can moderately 
alter some of these glycosyltransferase levels but show a stronger, combinatorial activation of 
transcription in double knockouts. 
To examine if BA overload could induce expression of glycosyl-transferases. RNA-seq 
analysis of Control+CA livers indicated no significant differences in glyosyltransferase levels 
compared to Controls (Supplementary Figure 2.5A-C), indicating that CA does not elicit a 
glycosylation response in mice. To test the effect of secondary BA excess in vitro, we treated 
primary hepatocytes with DCA. We found that 100 µM DCA, but not 50 µM (data not shown), 
was able to modestly suppress Mgat5, Fut8 and St6gal1 (Supplementary Figure 2.5D-F). This 




Fxr and Shp ablation results in depleted glycogen stores 
Since LDKO mice showed lower circulating glucose (Supplementary Figure 2.6A) and 
increased glycosylation ability (Figure 2.4, 2.5), we examined glycolytic genes and glycogen 
levels in LDKO livers. Genes regulating glycolysis remained unaltered (Supplementary Figure 
2.6B). Further, PAS staining exhibited severe loss of glycogen stores in LDKO livers 
(Supplementary Figure 2.6C). Overall, these findings indicate that liver Fxr-Shp axis is crucial 
not only to maintain BA levels but also to regulate glucose flux and glycosylation in the liver.  
 
LDKO livers exhibit structural and functional defects in Golgi apparatus 
 Since these above-mentioned glycan decorations, and protein sorting (Figure 2.4 and 2.5) 
occur in Golgi organelle, we imaged Control and LDKO livers using electron microscopy. 
Compared to the well-stacked Golgi ribbons in controls, we observed unstacked and dilated 
Golgi structure in LDKO livers (Figure 2.7A). To further analyze the functional capacity of 
Golgi, we measured the serum profiles of various metabolites that are secreted from the liver via 
trafficking through Golgi. Interestingly, albumin protein as well as a variety of lipids were 
altered in LDKO serum, compared to Controls (Figure 2.7B). These findings clearly indicate that 
ablation of FXR-SHP axis results in altered hepatic secretome and Golgi dynamics.  
 
FXR-SHP loss may result in compartmentalization of cholesterol in secretory vesicles 
A typical Golgi membrane is rich in cholesterol abundantly150. Since FXR-SHP are key 
cholesterol regulators, we stained intracellular cholesterol depots in Control and LDKO liver 
tissue sections and identified its enrichment in Golgi and secretory vesicles (Figure 2.8A). To 
identify a potential mechanism by which Fxr-Shp regulate Golgi structure and function, we 
analyzed and found a 10-fold induction in VAP protein levels. VAP interacts with OSBP (a 
cholesterol binding protein) and transports cholesterol from its site of synthesis, ER, to Golgi 
membrane (Figure 2.8B). This maybe a potential mechanism by which Fxr-Shp regulate Golgi 





 Cholestasis is a liver disease caused by restricted bile flow, leading to bile accumulation 
in the liver and serum. Genetic mutations in BA transporters151–154 and synthesis155,156 have been 
reported to cause progressive familial intrahepatic cholestasis. Nuclear receptor FXR coordinates 
with SHP to maintain BA homeostasis such that global Fxr and Shp deletion results in severe 
cholestasis and liver injury. Importantly, the individual Fxr and Shp knockouts do not exhibit 
these characteristics110, indicating their synergistic role in the liver. Since, the hepatic 
contributions of their regulatory networks have not been characterized, we generated liver 
specific Fxr-Shp double knockout (LDKO) mice. 
 Gross phenotypic characterization of LDKO mice neither displayed any developmental 
defect nor changes in liver size. Further, the gall bladder size was similar between LDKO and 
control mice (data not shown) since the Fgf15-FXR gut axis, which is responsible for gall 
bladder refilling157,158, is intact in the LDKO mice. Next, we fed both control and LDKO mice 
1% CA diet, which is known to cause liver injury159,160. LDKO mice on CA diet (LDKO+CA) 
lost more body weight on day 5 of CA diet compared to Control+CA mice. Further 
characterization showed elevated liver injury markers, including serum ALT and AST levels as 
well as BA pool. Additionally, LDKO+CA livers exhibited degenerating hypertrophic 
hepatocytes and focal inflammation, indicating that hepatic Fxr-Shp is responsible for protecting 
hepatocyte from BA-mediated injury. Despite unaltered bile acid levels in LDKO mice, they 
developed spontaneous liver tumors, highlighting another mechanism regulated by FXR-SHP. 
Since LDKO mice lack the Fxr-Shp mediated feedback inhibition of BA synthesis, CA 
diet did not repress BA synthesis genes (Cyp7a1, Cyp8b1) in LDKO compared to Control livers. 
Further, these genes were induced in LDKO+Chow mice, indicating the importance of FXR-SHP 
axis in keeping basal BA synthesis in check. Despite lacking Fxr-Shp hepatic axis, LDKO+CA 
livers did exhibit a less than two-fold repression of these genes that could be attributed to the 
presence of an intact intestinal FXR-FGF15-ERK axis in LDKO mice, which suppresses BA 
synthesis independent of hepatic Shp. This finding is in line with the previous studies that 
indicate that FGF15, induced by intestinal FXR, interacts with ERK to silence Cyp7a1 
transcription105. We also characterized the genes regulating the alternate BA synthesis pathway. 
Compared to the controls, Cyp27a1 was upregulated in Control+CA livers. This could be 
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advantageous since excess CA may be getting converted into a more hydrophilic (i.e. less toxic) 
muricholic acid161,162. Similar increases in fold change of Cyp27a1 was also observed in 
LDKO+CA, suggesting that this regulation does not require hepatic Fxr-Shp. Interestingly, 
Cyp7b1 displayed similar expression profiles as the classical BA synthesis genes. These findings 
indicate that liver Fxr-Shp axis is crucial in regulating BA synthesis genes and that loss of this 
network may upregulate BA metabolism and excretion as an adaptive strategy. 
As expected, FXR downstream target Bsep, the key biliary transporter, was robustly 
suppressed in LDKO mice. BA efflux into circulation was induced in LDKO+CA mice, which 
was consistent with the observed increases in serum BA levels. Also, BA uptake into the 
hepatocytes was reduced in LDKO livers. Thus, overall BA homeostasis95,97,163 was altered to 
accommodate for the deletion of Fxr-Shp regulation. Since intestinal BAs were high, we 
examined the ileum of LDKO mice and found no change in gross morphology as well as in the 
gene profiles (data not shown). This finding indicates that BA pools in the ileum are effectively 
recirculated or being excreted in feces. Examining fecal BA analysis would confirm this 
hypothesis. 
 To determine the transcriptional networks that are controlled by hepatic Fxr-Shp axis in 
an unbiased fashion, we performed RNA-seq analysis. Global transcriptome analysis uncovered 
a novel role for Fxr-Shp in regulating N-glycosylation status of liver proteins. Particularly, the 
“branching” glycosyltransferase Mgat5, core-fucosyltransferase Fut8 and sialyltransferases 
St3gal6 and St6gal1 were induced in the absence of Fxr and Shp. This gene expression data was 
substantiated by increases in core-fucosylation and triantennary complex branching of N-
glycans. Importantly, no differences were observed in mRNA levels of glycosyltransferase 
responsible for O-glycosylation (Ogt and Mgea5)127,129 or O-glycan profiles in LDKO livers 
compared to the controls (data not shown).  
 Next, we investigated the individual contributions of hepatic FXR and SHP in this 
glycosylation phenotype of LDKO livers. FXR displays a potential binding site within the 
intronic regions of Mgat5 gene and its activation results in decreased Mgat5 levels. Previous 
studies have shown that FXR can bind, decrease RNA polymerase II recruitment and act as a 
ligand-dependent transrepressor164,165. It is also possible that active FXR-mediated Shp induction 
can inhibit Mgat5 transcription since SHP is a well-known co-repressor. FXR deletion in LDKO 
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livers could relieve this suppressive effect, resulting in Mgat5 upregulation. ETS family of 
transcription factors have been previously shown to bind and drive Mgat5 transcription166. More 
recently, Src kinase has been implicated in regulating Mgat5 transcription in vitro167 and it has 
been shown that FXR antagonist promotes Src phosphorylation (Tyr416)168, which in turn could 
lead to higher Mgat5 levels. Together, these findings corroborate with our finding that Fxr can 
mediate regulation of Mgat5 levels. On the contrary, FXR activation showed no change in Fut8 
levels, despite a strong FXR binding site in the intronic regions of Fut8169. This raises the 
possibility that this FXR binding may be context dependent since the ChIP-seq was performed 
after overnight fasting (14 hours) whereas we performed gene expression analysis after 10 hours 
of fasting. It is known that Fut8 can be transcriptionally suppressed by hepatic nuclear receptor 
HNF1α170 and tumor suppressor P53171. LDKO livers show abrogation for HNF1α signaling 
(data not shown), which might be responsible for transactivation of Fut8. Moreover, FXR can 
repress P53 signaling in a SHP dependent manner172. Thus, loss of FXR-SHP axis may inhibit 
P53 repression, thereby allowing P53 to transactivate Fut8. On the other hand, St3gal6 does not 
harbor an FXR response element, but St6gal1 has a strong FXR binding peak within its coding 
regions. Nevertheless, we did not observe any alterations in St3gal6 or St6gal1 upon FXR 
activation, suggesting that Shp, being a well-known corepressor103,173,174, may suppress St6gal1. 
Interestingly, Liver specific Shp knockout mice showed upregulation of St3gal6 and St6gal1 
only, which suggest that Shp plays a major role as a corepressor for these genes. Overall, these 
findings indicate that Fxr and Shp signaling individually can moderately alter some of these 
glycosyltransferase levels but show a stronger, combinatorial activation of transcription when 
both of them are deleted. Previous studies have reported that toxic bile acids can suppress N-
glycosylation in vitro175–177. We found that CA feeding in Control mice did not mimic the LDKO 
phenotype, indicating that the changes in the glycosylation pathways are not due to subsequent 
increase in primary bile acids. However, pathological dose of DCA was able to suppress some of 
these glycosyltransferases in hepatocytes suggesting that secondary BAs may regulate 
glycosylation in the liver.  
Next, we examined the consequence of increased HBP and how it affects glucose levels 
in LDKO mice. Typically, glucose taken up by the hepatocytes undergoes three fate 
decisions178,179: (i) glycolysis, (ii) glycosylation, and (iii) glycogen synthesis. LDKO mice have 
lower systemic glucose levels and this coupled with lack in glycogen substantiates with the 
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increased flux of glucose into glycosylation. Gene expression profiling of glycolytic pathway 
showed no significant alterations. In vitro treatment with UDP-GlcNAc have been shown to 
induce glycosylation of various proteins180–183. Therefore, we can analyze levels of UDP-
GlcNAc and other intermediates of HPB pathway in both Control and LDKO livers.  
   Since the glycan decorations (core-fucosylation and branching) occur in medial- and 
trans-Golgi apparatus145,184, we examined and found unstacked and dilated Golgi in LDKO 
livers. This structural defect was unique to the Golgi apparatus but was not obvious in other 
cellular organelles including mitochondria and Endoplasmic reticulum. We further analyzed its 
secretory ability and found altered secretome of LDKO livers. This defect could be secondary to 
excess N-glycosylation or consequently improper Golgi structure could contribute to the excess 
glycosylation. Further studies will be needed to study this aspect of the project. Since all the 
protein processing and modifications, which are altered in LDKO livers, occur in Golgi 
apparatus, we think that Golgi structural defect results in the altered Golgi function. 
Since Fxr-Shp are one of the key regulators of cholesterol homeostasis, we examined if 
cholesterol levels are changed in the liver. Surprisingly, we did not see any significant changes 
(data not shown). However, previous studies have shown that intracellular cholesterol 
localization could change and affect various tissue functions. Additionally, Golgi membranes are 
known to be rich in cholesterol and it is important to perform vesicular transport. Therefore, we 
stained the control and LDKO liver sections for cholesterol and found its robust accumulation in 
Golgi and secretory vesicles. Further analysis revealed induction of a key intracellular 
cholesterol transport protein, VAP. Future studies on how Fxr-Shp regulate this cholesterol 
dynamics will be needed to explain this process.  
Several glycosyltransferases including Mgat5 and Fut8 are associated with cell-matrix 
and cell-cell contacts, thereby affecting cell signaling146–149,185. LDKO livers displayed increases 
in key regulators of cell adhesion, including cell-cell and cell-ECM interactions. These 
alterations in cellular signaling and adhesion are well known to induce carcinogenesis. 
Analyzing cell adhesion glycoproteins and examining their glycan decorations between control 
and LDKO livers will allow us to understand the cellular consequences of increased N-





Combined deletion of hepatic Fxr-Shp alters biliary homeostasis and response to BA 
overload. We discovered an unexpected role for Fxr-Shp in maintaining the glycosylation status 
of liver proteins. We found that hepatic Fxr-Shp network is required to maintain the expression 
of glycosyltransferases Mgat5, Fut8, St3gal6 and St6gal1. Importantly, Golgi structure and 
function are compromised in LDKO livers. We have identified that loss of hepatic Fxr-Shp axis 
results in increased compartmentalization of cholesterol in Golgi apparatus and secretory 
vesicles. This may be a potential mechanism by which Fxr-Shp networks controls Golgi 












2.7. Figures and Legends 
 
Figure 2.1: Global loss of FXR-SHP (DKO) livers develop severe toxicity and cancer.  
(A) Hematoxylin & Eosin staining show injury, focal inflammation and necrosis in DKO livers. 
Arrow: Hepatocyte degeneration, yellow circle: inflammation, black circle: necrosis. Scale: 100 
(B) Serum bile acid levels indicate cholestasis only in DKO mice, and not in individual FXR and 
SHP knockouts. (C) DKO livers undergo spontaneous tumorigenesis. (D) Schematic figure 






Figure 2.2: LDKO mice develop cholestasis and exhibit severe liver injury when challenged with 
BA diet.  
(A) Hematoxylin and Eosin staining suggests mild injury in Control+CA, moderate in 
LDKO+Chow and severe in LDKO+CA livers. Circle represents focal inflammation and arrows 
mark ballooning degeneration. Scale bar: 50µ. (B) Serum liver enzymes, ALT and AST as well 
as (C) serum and hepatic BA levels indicate liver damage and cholestasis respectively in 
LDKO+CA mice compared to the controls (n=6-11 mice per group). (D) LDKO livers develop 




Figure 2.3: BA homeostasis machinery is disrupted in LDKO mice on CA diet. 
qRT-PCR analysis was performed on the genes regulating (A) classical BA synthesis, (B) BA 
efflux into canaliculi, (C) BA efflux into circulation, (D) BA uptake into hepatocytes and (E) BA 
metabolism. (n=4-6 mice per group). 
 






















































































































Figure 2.4: Transcriptomic analysis reveals upregulation of glycosylation pathway in LDKO 
mice.  
RNA-seq was performed on the livers of chow-fed Control and LDKO mice. (A) The volcano 
plot and the pie chart represent the globally upregulated and downregulated genes in LDKO mice 
compared to the controls. (B) Functional clusters display the enrichment of glycosylation upon 
Fxr-Shp deletion. Blue circles: downregulated, Red circles: upregulated. (C) Heat map shows 
that liver Fxr-Shp control the mRNA expression of N-linked glycoproteins. (n=3 mice per group, 
fold change >1.5, p-value <0.05). (D) RNA-seq data revealed upregulation of 
glycosyltransferases that “decorate” glycoproteins in LDKO livers (n=3 mice per group, fold 




Figure 2.5: Fxr-Shp ablation results in hyperbranching of the glycoproteins. 
Addition of branching or variations in glycan moieties result in protein microheterogeneity that 
is associated with injury, cell adhesion and cancer. (A) Pie chart depicts increased core-
fucosylation in LDKO livers (n= 5 mice averaged per group). (B) Bar graph exhibits higher 
percentage of triantennary glycans in LDKO liver compared to controls. (n= 5 mice averaged per 
group). (C) Glycoproteomic analysis reveal increased hyperbranching of proteins present in 
exosome, ER and lysosome. (n=5 livers pooled per group). (D) HCD MS2 fragmentation 
spectrum of triantennary N-glycopeptide VVLHPNHSVVDIGIGLIK from haptoglobin. (E) 
Relative ratio of sialylated and fucosylated glycoforms with respect to high mannose type N-




Figure 2.6: Individual FXR and SHP signaling can contribute to some of the changes in 
glycosyltransferase expression observed in LDKO. 
qRT-PCR analysis was performed on (A-B) FXR-activated (treated with GW4064, FXR 




































































































Figure 2.7: Golgi structural and functional defects in LDKO livers.  
(A) Electron Microscopy imaging shows unstacked Golgi apparatus (arrowheads) in LDKO 
livers compared to Controls. (B) Secretory ability of LDKO livers is altered as quantitated by 
serum levels of albumin (a), cholesterol (b), phospholipids (c), HDL (d), LDL and VLDL (e) and 
































































Figure 2.8: LDKO livers may show accumulation of cholesterol in Golgi and secretory vesicles. 
(A) Filipin stains for cholesterol in LDKO and Control liver sections. (B) The ER resident VAP 


























Figure 2.9: Schematic figure proposing the mechanism by which FXR- SHP may regulate 


































2.8. Supplementary Figures, Tables and Legends 
 
Supplementary Figure 2.1: Characterization of LDKO mice. 
(A) Genotyping confirms Fxr and Shp knockout in mouse livers. (B) qRT-PCT analyses reveals 
a robust knockdown of both Fxr and Shp transcripts in LDKO livers. (n=6-10 mice per group). 
(C) CA feeding causes a modest weight loss in LDKO mice, and a subsequent increase in liver-
to-body weight ratio. (n=6-10 mice per group). (D) Gross liver pictures from control as well as 







Supplementary Figure 2.2: Aberrations in BA homeostasis genes are exacerbated upon CA diet. 
Genes regulating alternative (A) BA synthesis, (B) BA efflux into bile and circulation were 




















































Supplementary Figure 2.3: LDKO livers exhibit induced core-fucosylation and glycan branching 
of glycoproteins. 
(A) qRT-PCR analyses of these glycosyltransferases validate the RNA-seq data. (n=8 mice per 
group). (B) Pie charts show no significant change in mannosylated and sialylated glycoproteins. 


















































Supplementary Figure 2.4: Cell adhesion genes were upregulated in LDKO livers. 
Heat map suggests alterations in genes regulating cell-cell and cell-ECM interactions in LDKO 






Supplementary Figure 2.5: Effect of BA overload on expression of glycosyltransferases  
We determined the consequence of excess bile acid in vivo and in vitro. (A-C) CA feeding does 
not alter mRNA levels of key glycosyltransferases. (n=3 mice per group). (D-F) On the contrary, 
qRT-PCR analysis shows downregulation of Mgat5, Fut8 and St6gal1 upon DCA incubations in 




















































































Supplementary Figure 2.6: LDKO livers exhibit depleted glycogen stores. 
(A) LDKO mice have reduced blood glucose levels. (n=12-15 mice per group). (B) A panel of 
bar graphs comparing FPKM values of glycolytic genes between Control and LDKO livers. (n=3 
mice per group). (C) PAS staining indicates lower glycogen content in LDKO livers. (n=5 mice 









Primer 1 ATGTGTTCTAAGCTAGACATGG 95°C 5min
Primer 2 GAAGCACACTCACAGATGTCA 95°C 30sec




Primer 1 TAGTTGCTTGTGGAAAGGACCAACC 95°C 5min
Primer 2 CTAGGAAGTGAAGTGGCCTTGTCTG 95°C 30sec




Primer 1 GAACCTGATGGACATGTTCAGG 94°C 3min
Primer 2 AGTGCGTTCGAACGCTAGAGCCTGT 94°C 30sec







Supplementary Table 2.2: qRT-PCR primer sequences used. 
  




Cyp27a1 CCTACATCCATTCGGCTCT CCAGGGCAATCTCATACTTC 
Cyp7b1 GACGATCCTGAAATAGGAGCACA AATGGTGTTTGCTAGAGAGGCC
Bsep CCAGAGGCAGCTATCAGGAC CACACAAAGCCCCTACCAGT
Mdr1a GGCACAAACCAGACAACATAC    GTCCGCTCTTCACCTTCAG    
Mrp2 GGAGGAAGTAGTGAAAGGACA    GAAGATGACGATGAAGAGCAG    
Mrp3 ATCATTGTGCTTGCTGGTG    CTCCTGGTCTTCATCTGGTG    
Mrp4 CATTTATCGTCCTCCCTCCA GGAACAAGAACCAAGCCTCT 
Ntcp CTCAGCGTCATTCTGGTAGTT CCAGAAGTGAGCCTTGATCTT
Oatp1 GTATTCCCCGTCCTCCAAT    CCCCTACACATTCGTGACTT    




Ugt1a1 ATG GCT TTC TTC TCC GGA AT TCA GAA AAA GCC CCT ATC CC 
Shp GGTCCCAAGGAGTATGCGTA AGGGCTCCAAGACTTCACAC 
Mgat5 GTTCCCTCATACCCCAGACA    CCACTTTGCCATACACAAGG    
Fut8 CTTGATTCGTCCACAACCTT    GCTGCTTCTGTTCCCACTTT    
St3gal6 CCGTTGCCCTATGGAATAAA    CCATTACCAACCACCACACA    
St6gal1 GCTGCTTTGTCCTGGTCTTT    CCACTTTCTCCTGGCTCTTC    
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CHAPTER THREE: GENOME-WIDE ANALYSES OF VARIOUS LIVER DISEASES 
REVEAL UNIQUE UPREGULATION OF DRUG METABOLISM IN CHOLESTASIS 
Mathur B1, Arif W2, Patton M1, Faiyaz R3, Kalsotra A2, Wheatley AM3 and Anakk S1 
 
1Department of Molecular and Integrative Physiology, 2Department of Biochemistry, University 
of Illinois at Urbana-Champaign, Urbana, IL and 3Department of Physiology, School of 
Medicine, National University of Ireland Galway, Ireland 
 
3.1. Abstract 
 Understanding the alterations in drug metabolism in different liver diseases is crucial for 
appropriate therapeutic intervention. We performed high-throughput RNA sequencing on various 
liver injury models, including cholestasis, diet-induced steatosis, and regeneration. Comparative 
liver transcriptome analysis revealed overlapping and distinct gene profiles among different liver 
diseases. Particularly, cholestatic livers displayed robust induction of drug metabolizing genes. 
This upregulation is not a generic hepatic stress response, as it was suppressed or unchanged in 
other models of liver diseases. Consistently, drug metabolic gene profiles were induced in a 
subset of biliary atresia patients, but not in individuals with hepatitis B or C viral infection, and 
alcoholic hepatitis. Further analysis revealed this induction was specific to genes regulated by 
nuclear receptor CAR (Constitutive Androstane Receptor). To test this, we challenged 
cholestatic mice with a paralytic agent, zoxazolamine. Compared to controls, these mice 
displayed significantly reduced paralysis time, reflecting increased drug metabolism. 
Importantly, this effect was lost upon inhibition of CAR activity. Further, since CAR 
metabolizes a wide array of prescription drugs, we tested and observed that these cholestasis 
mice are protected against necrosis induced by the most common drug, acetaminophen 
(painkiller). This protective response was attributed to increased bile acid load in cholestatic 
mice, which can cause liver proliferation. These new hepatocytes, in turn, protect against the 
necrotic effect of acetaminophen. In conclusion, we found that increased drug metabolism is not 
a common hepatic stress response, but unique to cholestasis. Our data emphasize on the need for 
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 The liver plays a fundamental role in drug metabolism and detoxification. It is known 
that multiple factors, including genetics, diet, alcohol and viral infections can compromise its 
function. For instance, cholestatic liver disease can be drug-induced or secondary to mutations or 
due to immune modulation 186,187,188. On the other hand, high-fat and western-diet primarily drive 
the development of fatty liver disease, while excess alcohol consumption, hepatitis B and C 
infections can lead to cirrhosis and eventually cancer. As different therapeutic interventions are 
employed to treat these conditions, it is important to understand the molecular networks that are 
perturbed during these disease states.  
 Here, we used an unbiased high throughput approach and performed comparative 
analysis of transcriptome of different liver diseases to identify the common and distinct gene 
signatures between them. RNA-sequencing data from mouse models of cholestasis, diet-induced 
fatty liver disease and liver regeneration revealed alterations in genes involved in inflammation, 
proliferation, and lipid metabolism. Intriguingly, CYP450 pathway was specifically upregulated 
in cholestatic livers, whereas it was downregulated in steatosis and regeneration. To examine if 
this expression pattern is maintained in humans, we analyzed publicly available liver 
transcriptome datasets of Hepatitis B and C viral infections 189, alcoholic hepatitis 190, and biliary 
atresia 191. We did not find upregulation of P450s in any of the conditions except for a subset of 
biliary atresia patients with extremely high GGT levels.  
 This is surprising since liver function is compromised during cholestasis, one would 
anticipate reduced metabolic capacity. Such confounding data have been reported, in the context 
of Primary Biliary Cirrhosis (PBC), liver cirrhosis, and biliary obstruction 192–194. However, 
increased drug clearance during cholestatic liver diseases have been previously noted 195,196. It is 
important to note that some of the phase I metabolic genes such as Cyp2bs and Cyp3as can 
hydroxylate and facilitate bile acid (BA) excretion 197. 
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 The major regulators for phase I xenobiotic metabolism are nuclear receptors 
Constitutive Androstane Receptor (CAR) and Pregnane X Receptor (PXR) 119. Therefore, we 
examined the Phase I genes in cholestasis mouse model and found a significant correlation with 
CAR activation, while Phase II genes correlate with activation of both CAR and PXR. We also 
determined that the observed increase in detoxification machinery is associated with the BA 
burden. Taken together, our findings reveal that CAR activation in cholestasis may occur to 
promote BA excretion but leads to unintended consequence of increased drug clearance.  
 
3.3. Materials and Methods 
Animals 
Fxr-/- Shp-/- (DKO) male mice were generated as previously described 110. Age matched 
wild-type (WT) males were used as controls. Individual floxed-Fxr and floxed-Shp mice 
obtained from Dr. Kristina Schoonjans’s laboratory were intercrossed to generate double floxed 
homozygous Fxr-Shp mice (fl/fl Fxr fl/fl Shp). Mice were maintained on C57BL/6J background 
and housed on a standard 12-hour-light/dark cycle. All the experiments were carried out on 12-
16 weeks old male mice, unless specified, as outlined in the Guide for the Care and Use of 
Laboratory Animals, the National Academy of Sciences (NIH publication 86-23, revised 1985) 
and approved by the Institutional Animal Care and Use Committee at University of Illinois, 
Urbana-Champaign. To test if increased detoxification is a generalized injury response of the 
liver, following experimental cohorts were used- (i) Bile acid-induced stress: fl/fl Fxr fl/fl Shp 
mice were fed with either normal chow or 1% Cholic Acid (TD.140532) diet for 5 days. (ii) 
High-fat diet induced fatty liver: WT mice were fed either a chow or 60% fat containing diet 
(TD.06414) for 8 weeks. (iii) Liver regeneration model: Livers from C3H/HeN mice were 
collected 48 hours post 2/3rd partial hepatectomy (PHx) to determine if CAR is activated in the 
regenerating liver. All the mouse diets were obtained from Harlan (Envigo). 
 
Chemicals 
Murine CAR agonist TCPOBOP (1,4-Bis [2-(3,5-dichloropyridyloxy)] benzene), referred 
here as TC, was obtained from Sigma. TC was first dissolved in 100% ethanol at a concentration 
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of 4 mg/ml, followed by dilution in corn oil and stirred overnight to make a final concentration 
of 2 mg/ml. Thirty-six hours after a single intraperitoneal injection with corn oil or 3 mg/kg TC, 
WT mice were sacrificed to collect livers. WT and DKO mice were injected intraperitoneally 
once with either 250 mg/kg zoxazolamine (Sigma) alone, or with 100 mg/kg androstanol 
(Sigma), 3 days prior to zoxazolamine treatment to inhibit CAR activity. For acetaminophen 
treatments, WT and DKO mice were fasted overnight, followed by a single intraperitoneal 
injection with 0.9% saline or 300 mg/kg acetaminophen. The mice were then sacrificed to collect 
liver and blood serum after 6 and 24 hours. A zero-hour time point was used as controls. 
 
Histology and Immunofluorescence Staining 
Liver tissues were fixed in 10% Formalin for 24 hours, processed and embedded in 
paraffin. Liver sections were cut to obtain 5 thick slices, followed by deparaffinization in 
xylene and ethanol (100%, 95%, 80% and 50%) and rehydration in water. These slices were 
stained with Hematoxylin and Eosin as per manufacturer’s protocol.  
For immunofluorescence staining, the rehydrated sections were antigen retrieved in Tris-
EDTA buffer (pH 8.0) in a slow cooker at 90 °C for 5 min, followed by cool down in cold tap 
water. Next, the sections were washed in Tris-buffered saline (TBS) + 0.05% Triton X-100 
buffer twice for 5 minutes and blocked in 10% normal goat serum and 1% BSA at room 
temperature for 2 hours. Post blocking, anti- CYP2B (Origene, Catalog# TA504328) were 
applied to the sections at 1:100 dilution and incubated overnight at 4 °C. Following this, the 
sections were washed in TBS+ Triton X-100 buffer, and secondary fluorescent antibodies (Goat 
anti-mouse, 1:500 in 1% BSA + TBS) were applied for 1 h at room temperature. The sections 
were then coverslipped using CC/Mount aqueous mounting media (Sigma) and imaged on Zeiss 
LSM 710 microscope at Institute for Genomic biology (IGB) core facility, UIUC. 
 
RNA-Seq analysis 
RNA was isolated using RNeasy tissue mini-kit (Qiagen) from the livers of the following 
cohorts of mice: Cohort I: Chow fed WT and DKO (Fxr-/-Shp-/- double knockout) mice, Cohort 
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II: Corn Oil- or TC-treated WT mice, Cohort III: Chow or High fat diet-fed WT mice, Cohort 
IV: Sham- or partial hepatectomized (PHx) mice, Cohort V: Chow- or Cholic acid (CA)-fed 
mice. RNA quality was tested using an Agilent bioanalyzer by the Functional Genomics Core at 
Roy J. Carver Biotechnology Center, UIUC. Hi-Seq libraries were prepared and Illumina 
sequencing was performed on a HiSeq 4000 at the High Throughput Sequencing and Genotyping 
Unit, UIUC. The sequencing details are outlined in Supplementary Table 3.3. Reads were 
processed for quality using Trimmomatic and aligned to the mouse genome (mm10) using 
STAR. Read count values and differential gene expression were obtained from HTseq and 
DESeq2 respectively. Fold change >1.5, calculated relative to the respective controls, was 
considered significant. Log2 fold change was plotted as heat maps. Upregulated and 
downregulated genes were clustered into biological pathways using DAVID Gene-Ontology tool 
(https://david.ncifcrf.gov/tools.jsp). 
The data discussed in this publication have been deposited in NCBI's Gene Expression 
Omnibus 198 and are accessible through GEO Series accession number GSE116627 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116627). 
 
Quantitative Venn Diagrams 
BioVenn 199 was used to generate Venn diagrams comparing the overlapping Phase I and 
Phase II metabolic genes between the following groups: Group I: DKO, CAR-activated and 
PXR-activated mice, Group II: 5 weeks old DKO, Fxr-/- (FXRKO), Shp-/- (SHPKO) mice 110, 
Group III: DKO and Cholic Acid (CA)-fed mice. Genes showing similar trend to DKO 
directionally were included. Difference of >25% in gene expression between the groups was 
considered significant. 
 
Analysis of Serum Bile acid composition 
Pooled serum from either DKO, CA-diet fed mice or their respective controls (n=5 mice 
per group) was quantitated for individual bile acid species using liquid chromatographic–mass 
spectrometry at Metabolomics Core (Baylor College of Medicine, Houston). A Waters Acquity 
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UPLC BEH C18 column was used. L-Zeatine was spiked into each sample as an internal 
standard. 
 
Hepatic Glutathione Assay 
Total hepatic glutathione disulfide (GSH) levels were measured in liver homogenates 
from WT and DKO mice post acetaminophen treatments using Glutathione Assay Kit (Sigma-
Aldrich, St. Louis, MO), according to the manufacturer’s protocol. Briefly, total GSH was 
extracted from liver lysates in 5% sulfosalicylic acid and oxidized to GSSG by 5,5′-dithiobis-(2- 
nitrobenzoic acid). This is followed by addition of NADPH to measure the rate of GSH 
formation in the presence of glutathione reductase kinetically at 412 nm. 
 
Quantitative real time PCR (qRT-PCR) Analysis 
RNA was isolated from WT and DKO livers (n=5 per group) using TRIzol (Invitrogen), 
reverse-transcribed, and analyzed by SYBR® Green™ based qRT-PCR. Mouse specific primer 
sets are listed in Supplementary Table 3.2. Relative gene expression was calculated by delta-
delta Ct method, and normalized to 36b4 levels as loading control. 
 
Statistics 
Data is presented as mean ± standard error of mean (SEM). Unpaired Student’s t test was 
used to compare between WT and DKO. One-way ANOVA with a Bonferroni post-hoc test was 
used for the zoxazolamine experiment. All statistical analysis was done using Graphpad Prism. 







Transcriptomic profiling of diseased murine livers revealed upregulation of genes involved in 
metabolism during cholestasis. 
 Liver is a central hub responsible for the breakdown of carbohydrates, fat, protein and 
foreign compounds including prescription drugs. To examine how transcriptional liver networks 
are altered during different liver injuries, we performed and analyzed RNA-seq on cholestatic, 
fatty and regenerating mouse livers. Global deletion of both Farnesoid X Receptor (Fxr) and 
Small Heterodimer Partner (Shp) (DKO) resulted in cholestasis, which is excessive accumulation 
of bile acids (BA) 110 200. Histological analysis of DKO livers showed liver injury such as 
hepatocyte ballooning, ductular reactions, and focal inflammation, consistent with severe 
cholestasis. Further, high fat diet fed mice developed macro-steatosis and accumulated large lipid 
droplets in the liver and partial hepatectomy resulted in a robust regenerative response, which is 
indicated by the presence of mitotic bodies (Supplementary Figure 3.1). We found overlapping 
and distinct gene programs switched on in the livers after these different conditions (Figure 
3.1A). Gene ontology analysis of overlapping pathways specifically enriched the cellular 
proliferative response. Interestingly, many metabolic pathways were up regulated, while DNA 
damage, hypoxic and insulin response were down regulated during cholestasis (Figure 3.1B). On 
the other hand, high fat diet-fed mice as expected showed upregulation of genes related to lipid 
transport, immune response activation, and acyl coA metabolic pathways. Downregulated genes 
were related to glucose homeostasis, oxidation-reduction, steroid, and P450-dependent metabolic 
pathways (Figure 3.1C). Regenerating livers showed upregulation of genes related to cell cycle, 
mitosis, and acute phase response, and downregulation of oxidation-reduction, steroid, glucose, 
and P450-dependent metabolic pathways (Figure 3.1D).  
 Thus, an increase in metabolic gene profile of the liver is not a general liver injury 
response but is rather specific to cholestasis. We focused our interest on drug metabolism and 
examined the transcriptome of CA-fed WT mice livers. In addition to induction of cell cycle and 
mitosis related genes, CA diet caused pronounced upregulation of oxidation-reduction, 
glutathione metabolism, and cellular drug response pathways (Supplementary Figure 3.2A). 
These results demonstrate that BA overload can activate cytochrome P450s, and subsequently, 
drug metabolizing phase I and phase II genes as observed in DKO mice (Supplementary Figure 
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3.2B, C). We examined the circulating BA composition between CA-fed control and DKO mice 
(Supplementary Figure 3.2D) and found increases in both 6 (all muricholates) and 12 hydroxy 
BAs (both DCA and CA) as previously reported 110 201.  
 To ascertain if phase I metabolism is induced in human liver diseases, we analyzed the 
liver transcriptome post-HBV or -HCV infection 189 to determine if the drug metabolic changes 
are secondary to viral infection and/or inflammation. In this group, we separated the samples into 
two cohorts based on whether the disease progressed to hepatocellular carcinoma (cHBV, 
cHCV) or not (HBV, HCV). Additionally, we mined the transcriptomic data from patients with 
severe alcoholic hepatitis 190. The transcript changes displayed overlap between HBV and HCV 
cohorts but were distinct from alcoholic hepatitis group (Figure 3.2A). We did not find any 
alteration in the detoxification machinery (Figure 3.2B, C) post HBV or HCV infection, whereas 
in alcoholic hepatitis, phase I and II genes, except Cyp1B1 and Sult1C2 were down regulated 
(Figure 3.2B, C). Also, many of the Cyp genes were significantly decreased in cHBV group, 
while specific downregulation of Cyp2B6, 2C19 and 3A4 was observed in cHCV cohort (Figure 
3.2B). On the other hand, Phase II genes, Sult1C2 and Ugt1A6, were upregulated in both cancer 
groups (Figure. 3.2C).  
 Furthermore, cholestasis subsequent to deletion of Bsep, a major BA canalicular exporter, 
did not activate, but suppressed, phase I metabolism 202. Notably, their overall serum BA levels 
were dramatically lower compared to DKO mice 200, suggesting that a particularly high threshold 
of BA concentration in hepatocytes may promote detoxification pathways such as Phase I and II, 
as a fail-safe mechanism to hydroxylate and excrete BAs.  
 
A common overlap is observed between DKO livers and CAR/PXR activation gene signatures. 
 It is well known that nuclear receptors Constitutive Androstane Receptor (CAR) and 
Pregnane X Receptor (PXR) play a crucial role in the regulation of detoxification machinery 
116,117. Therefore we performed transcriptome analysis of livers after activation of CAR (TC 
treated) and compared the transcriptome with the previously published PXR-activated (PCN 
treated) data set 203 (Figure 3.3A, B) to identify which of these two programs were contributing 
towards the increased expression of drug metabolizing genes in the cholestatic DKO livers. As 
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expected, TC and PCN treatment induced pathways associated with oxidation-reduction, 
xenobiotic, and steroid metabolism (Figure 3.3A and B). We also found a strong upregulation of 
cell cycle associated transcripts with TC, but not with PCN treatment, suggesting that CAR may 
play an important role in controlling liver proliferation. 12-week-old DKO livers revealed an 
85% (11/13 genes) overlap with the CAR activated, and 37.5% (3/8 genes) overlap with the PXR 
activated, phase I gene signatures (Figure 3.3C). We found that the overall transcript changes in 
DKO livers displayed a 37% overlap with CAR activation (Supplementary Figure 3.3A). 
Moreover, we examined and found 61% of Phase I and 28% of Phase II gene targets altered in 
the DKO mice overlapped with that of TC-treated WT mice (Supplementary Figure 3.3B, C). 
 We then examined individual gene expression of Phase I genes and compared their 
expression pattern across the different cohorts (Figure 3.3E). As expected, Cyp2bs, and 2cs were 
more responsive to CAR, while Cyp3as were more responsive to PXR (Figure 3.3E). CA-fed 
livers displayed increases in Phase I genes, mimicking the profile of cholestatic DKOs. 
Compared to our previous microarray-based analysis of 5-week old DKO livers 110, RNA-seq 
results from 12-week old DKO mice showed broader, and more robust differences in gene 
expression (Figure 3.3E, Supplementary Figure 3.4). This indicates that worsening of cholestatic 
injury with age triggers a stronger and more extensive compensatory response. Further, forty-
eight hours post partial hepatectomy (PHx), all the Cyp genes remained suppressed, consistent 
with reduced metabolic function during regeneration 204. Many cytochrome P450 genes were 
downregulated in diet-induced steatosis, except for Cyp2b9, Cyp2b13, Cyp2a4 and Cyp2a22 
(Figure 3.3E) as previously described 205. These increases in Cyps could be attributed to 
glucocorticoid receptor signaling, which is enhanced in steatosis 206.  
 Phase II sulfotransferase (Sult) genes were robustly induced only in DKO and TC-treated 
WT mice. Whereas, increases in glutathione sulfotransferases (Gsts) were observed in DKO, 
CA-fed, PCN- and TC- treated mice. None of the Gsts were increased in the steatotic and 
regenerating livers, except Gsta1 (Figure 3.3F). The expression of phase II genes in DKOs was 
similar between activation of either PXR (7/16) or CAR (9/16) (Figure 3.3D), indicating that 





Fxr and Shp network can interact with the detoxification pathway.  
 FXR can induce PXR 207, and alter Cyp3A4 expression in humans 208, therefore we 
examined the consequences of Fxr or Shp deletion on detoxification machinery. We compared 
the CAR-PXR signatures between DKO, FXR knockout (FXRKO), and SHP knockout 
(SHPKO) livers. Cyp2b and Cyp2c gene expression profiles in FXRKO and SHPKO did not 
match that of DKO livers. However, Cyp2a5 expression showed dependency on FXR 
(Supplementary Figure 3.4A, B). Interestingly, 85% (6/7) of Phase II genes induced in DKO 
overlapped with FXRKO except for Sult2a1 (Supplementary Figure 3.4C, D). On the contrary, 
SHPKO livers had lower Gsta1, 2 and Gstm2, 3 (Supplementary Figure 3.4C). Next, we 
evaluated a role for human Fxr and Shp in xenobiotic metabolism, since we know that expression 
of both these nuclear receptors are reduced during biliary atresia 209 . We used previously 
published data 191 and compared biliary atresia samples with each other (22-169 days old) rather 
than comparing with control deceased liver samples (1.8 - 3.5 years old), since Cyp expression 
changes markedly with age 210. We found that xeno-sensing gene expression pattern segregated 
into three categories based on gamma-glutamyl transferase (GGT) levels - low (<450 U/L; 
n=21), mid (450-850 U/L; n= 31), or high (>850 U/L; n=17) (Figure 3.4A, B, Supplementary 
Figure 3.5A, B). It is important to note that out of the 69 biliary atresia samples, about 25% fall 
into the high GGT category. Interestingly, the expression profiles of several phase I genes 
including Cyp2C8 and Cyp3A4 genes were induced in high GGT samples (Figure 3.4A). 
However, the high coefficient of variation (97.40%) in Cyp2B6 expression in the low GGT group 
did not allow for statistical significance. Gene expression profile of mid GGT group revealed a 
similar trend to that of high GGT (Supplementary Figure 3.5A). In contrast to phase I changes, 
most of the phase II genes remained unchanged during biliary atresia, except for reduction in 
Sult1E1 and Ugt3A1 expression (Figure 3.4B, Supplementary Figure 3.5B). It is important to 
note that these two genes are known to be suppressed upon CAR and PXR activation 211–213, 
indicating that the xenosensing mechanism may be active in patients with high GGT, which 
represents about 25 percent of the biliary atresia patients.  
 We additionally examined if there is a correlation of Fxr gene expression with phase I or 
II genes. Interestingly, we did not see any correlation of Fxr expression with either Car or Pxr 
(Figure 3.4C) but found a direct correlation of Fxr with Cyp3A4 as previously reported 208 and 
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with Cyp2C8 (Figure 3.4D). This Cyp2C correlation with Fxr could be secondary to hepatocyte 
nuclear factor 4 (Hnf4) activation, which is known to regulate Cyp2C8 214. Similarly, Sult1E1 
associated with Fxr in the low GGT samples (Figure 3.4E). Next, we examined correlations with 
Shp expression and observed a positive trend with CAR and PXR at the high GGT group 
(Supplementary Figure 3.6A). Shp expression did not associate with Cyp3A4 nor Cyp2C8 
(Supplementary Figure 3.6B), nor with Sult1E1 nor Ugt3A1 (Supplementary Figure 3.6C), 
suggesting that loss of expression of SHP is not responsible for the increase in detoxification 
genes observed in cholestasis.  
 
CAR is responsible for increased phase I gene expression in cholestasis. 
 We validated our RNA-seq data such that many of the phase I and II genes were induced 
in the cholestatic DKO mice (Supplementary Figure 3.7A). Cyp2b10 and Cyp3a11 are murine 
homologs of human Cyp2B6 and Cyp3A4. It is well known that Cytochrome P450s (Cyps) are 
responsible for oxidative metabolism 215, with CYP2Bs and CYP3As carrying out phase I 
metabolism of many prescription drugs (Supplementary Table 3.1). We also analyzed Cyp2B 
protein expression and found its levels increased in DKO livers compared to WT (Figure 3.5A). 
Since DKO mice displayed higher expression of drug metabolizing genes, we tested its 
functional relevance. WT and DKO mice were treated with the paralytic agent zoxazolamine, 
and paralysis time was measured. Consistent with the observed increases in the detoxification 
machinery, DKOs showed lower paralysis time compared to WT mice (Figure 3.5B). Next, we 
tested if this is secondary to CAR activation in the DKO animals by pretreating mice with a CAR 
inverse agonist Androstanol to inhibit CAR activity. We found that androstanol significantly 
increased paralysis time in WT, indicating that CAR downstream target genes are important to 
clear Zoxazolamine (Figure 3.5B). Notably, DKO mice also lost their increased drug clearance 
capacity when treated with androstanol, indicating that CAR activation in DKO mice contributes 





Bile acid overload-mediated regeneration in cholestatic hepatocytes protect against drug-
induced necrosis. 
 WT and DKO mice were challenged with the common prescription drug, acetaminophen 
(APAP), which is known to cause hepatotoxicity and cell death. We found that DKO mice were 
protected against the necrotic effect of APAP (Figure 3.5C-E, Supplementary Figure 3.7B), 
which is attributed to increased hepatic bile acid content as previously shown216. This finding 
highlights that not only CAR activation but bile acid excess could also contribute to altered 
response to drugs upon cholestasis.  
 
Several studies in the 1970s reported faster clearance of drugs in patients with liver 
disease. For instance, tolbutamide was metabolized faster in cholestatic patients (165 ± 48 min) 
compared to normal individuals (384 ±76 min) 217. Patients with chronic alcohol consumption 
had higher metabolism of antipyrine (11.7 hr vs. 15.7 hr), phenobarbital (26.3 hr vs. 35.1 hr), and 
warfarin (26.5 hr vs. 41.1 hr) compared to controls 196. It is important to note that many of these 
drugs are prototypical substrates of the CAR/PXR target genes Cyp2C, 2B, or 3A 
(Supplementary Table 3.1). Taken together, our findings implicate that hepatobiliary damage can 
activate the CAR-PXR network or proliferating capacity in the liver, which in turn leads to 
unexpected increases in drug metabolizing ability (Figure 3.6).  
 
3.5. Discussion 
 Liver is a central organ responsible for drug metabolism and breakdown, therefore it can 
directly affect therapeutic efficacy. Many liver diseases with different etiologies exhibit varying 
levels of bile acid (BA) accumulation 218–220. Due to their detergent nature, BAs, when in excess, 
can also disrupts cell membranes, injures liver cells, and cause cell death 188. Therefore, BA 
concentrations are tightly controlled and in fact, BAs auto-regulate their concentrations via the 
nuclear receptors FXR and SHP 103,221. In this study, we took a genome-wide approach to 
investigate pathways that are altered under different conditions of liver diseases using mouse 
models and by mining publicly available human data. We used Fxr and Shp double knockout 
mice which mimics both juvenile 110 and neonatal cholestasis Progressive Familial Intrahepatic 
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Cholestasis 5 (PFIC5) 155 along with fatty and regenerating murine livers for our analysis. We 
were intrigued to find an increase in metabolic gene expression specifically during cholestasis. 
This was confounding, as one would expect diseased livers to have poor metabolic function. 
Therefore, we compared RNA-seq analysis of different liver injury cohorts with activation of 
xenosensors CAR or PXR activated groups, since it was previously shown that activating CAR 
and PXR could detoxify and eliminate BAs 222. We also examined if individual loss of FXR and 
SHP can control targets of CAR and PXR and found a poor overlap of target gene expression 
between these groups. Further, FXRKO as well as SHPKO do not accumulate as much BAs 
compared to DKO or 1% CA-diet fed mice 110, indicating that excess BAs may be required to 
promote this activation.  
 To elucidate the clinical significance of these findings, we mined the available datasets 
for different liver disease states due to HBV or HCV infections, alcoholic hepatitis, and biliary 
atresia. Humans have lesser number of P450s compared to mice, but do have a number of allelic 
forms 223. Despite dissimilarities, it is well established that nuclear receptors CAR and PXR 
regulate xenobiotic metabolism, and contribute to overall drug clearance 224,225. In patients, we 
did not find increases in expression of drug metabolism genes in any of these liver disease 
conditions, except in biliary atresia samples with GGT levels >850U/L. While we do not know 
why such a significant correlation exists only in this high GGT group, it is important to note that 
this subset accounts for a significant 25 percent of these patients and shows induction in CAR-
PXR target genes. All biliary atresia patients displayed elevated conjugated bilirubin levels to the 
same extent (~5 mg/dl), which unlike serum GGTs, did not separate into distinct clusters.  
 Even though we see high expression at the gene level, we need to validate the P450 
activity in different human cholestatic conditions, which is challenging. Instead, we have 
validated these findings at the protein level using our cholestatic mouse model and found higher 
Cyp2B protein expression in DKO compared to WT mice livers.  
 Moreover, we tested the functionality of these changes by measuring the effect of 
zoxazolamine and acetaminophen in these animals and verified that these cholestasis mice have 





 In summary, we postulate that severely cholestatic human hepatocytes may mount 
detoxification response to alleviate some of the BA burden. Although this may be initiated for a 
beneficial purpose, it comes with adverse consequences in terms of therapeutic benefits. As 
Cyp2C8, 2B6 and 3A4 are responsible for the majority of therapeutic drug clearance, these 
findings pose a challenge in the management of disease in this subset of patients. These 
individuals will have lower therapeutic benefit since they will clear prescription drugs faster than 
normal patients, as previously reported with certain drugs (tolubutamide, warfarin, antipyrine 
and phenytoin) 196,217. Based on our study, we propose that monitoring serum GGT levels, 
combined with therapeutic dose adjustments will be invaluable for patients with overt cholestasis 
















3.7. Figures and Legends 
 
Figure 3.1: Genome wide profiling reveals common and unique gene networks in cholestasis, 
steatosis and regeneration. 
(A) Venn Diagrams represent overlap of downregulated and upregulated gene expression among 
cholestasis (DKO), diet-induced steatosis (HFD) and regeneration (PHx). DAVID Gene ontology 
pathway analysis was performed on upregulated and downregulated genes in (B) cholestatic, (C) 




Figure 3.2: Comparative transcriptomic analyses indicate that drug metabolism is not a 
generalized response to liver injury. 
Previously conducted microarray data analyses for liver injury models in patients like Hepatitis 
B and C, cancer associated HepB (c-HBV) and HepC (c-HCV), Alcoholic Hepatitis (GEO 
dataset: GSE28619) were mined for alterations in gene expression. (A) Venn diagrams show 
negligible overlap in gene expression among these liver diseases.  (B) Heat maps display no 
induction, but rather downregulation of Phase I and II drug metabolic genes in these diseases 




Figure 3.3: CAR target signatures are induced specifically in cholestatic conditions. 
Bar graphs show upregulated and downregulated biological pathways in (A) CAR-, and (B) 
PXR- activated livers (n=2-3 mice per group, Fold change >1.5, FDR <20). Venn diagrams show 
major overlap of (C) Phase I genes between TC-treated and DKO mice. (D) Phase II genes in 
DKO livers are equally spaced between TC- and PCN-treated mice. Numbers indicate total 
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Figure 3.3 (Con’t.)  
number of genes in individual conditions and overlap of DKO with TC and PCN (n=3 per group, 
Fold change > 1.5, p value <0.05). Heat maps show that the cholestatic DKO livers recapitulate 
profiles of (E) Phase I and (F) Phase II genes observed in TC treated (CAR activated) livers. 
Importantly, some of these gene changes were mimicked in bile acid (CA) diet, but not in PCN-
















Figure 3.4: Expression and correlation with FXR mRNA levels of detoxification genes change 
with circulating GGT levels. 
Based on drug metabolic gene expression, microarray data for Biliary Atresia (GEO dataset: 
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Figure 3.4 (Con’t.)  
IU/l (n=17). Box plots show relative expression for (A) Phase I and (B) Phase II genes. mRNA 
expression was normalized to the median value of the low GGT group (Student t test, *p <0.05). 
Scatter plots show the extent of correlation between FXR and (C) xenosensing nuclear receptors: 
NR1I3 (CAR) and NR1I2 (PXR), (D) phase I genes: CYP2C8 and CYP3A4, (E) phase II genes: 
SULT1E1 and UGT3A1. Pearson correlation coefficient test was performed. R-squared values 

















Figure 3.5: Altered drug metabolism in cholestatic mice is protective. 
(A) DKO cholestatic livers show increased immunofluorescence staining for CYP2B10 
compared to WT livers. Arrows show increases staining. (n=4-5 mice per group, Scale: 50µ). (B) 
Bar graph indicates that DKO mice recover faster post zoxazolamine (zox)-induced paralysis 
than WT mice. Inhibiting CAR activity with androstanol normalizes the difference in paralysis 
time between WT and DKO mice (n=3-4 mice per group, mean ± SEM, One-way ANOVA, **p 
<0.001). (C) H&E staining of WT and DKO livers, treated with APAP shows that DKO livers 
are protected against acetaminophen-induced necrosis. Scale: 100. (D) Serum levels of liver 
enzymes ALT and AST were measured. (E) Hepatic glutathione levels of WT and DKO mice 




























3.8. Supplementary Figures, Tables and Legends 
 
Supplementary Figure 3.1: DKO livers demonstrate ballooning hepatocytes, focal inflammation, 
ductular proliferation and necrosis. 
Hematoxylin and Eosin staining was performed on WT, DKO, HFD fed, CA fed, and PHx livers. 
DKO livers show hepatomegaly and various signs of injury. Inset displays ductular reaction. 
Black circle: necrotic patch, yellow circles: focal inflammation, white arrow: microsteatosis. As 
expected, HFD display fat accumulation in the liver, and CA diet and PHx livers exhibit 




Supplementary Figure 3.2: Bile acid overload is sufficient to elicit comparable detoxification 
response observed in DKO livers. 
(A) Bar graphs show upregulated and downregulated biological pathways in bile acid-stressed 
livers (n=2-3 mice per group, Fold change >1.5, FDR <20). Venn Diagrams display overlapping 
(B) Phase I and (C) Phase II genes between DKO and CA fed mice, indicating enhanced drug 
clearance in DKO livers as a specific response to increased bile acid levels (n=3 per group, Fold 
change > 1.5, p value <0.05). (D) Bile acid composition analysis reveals increased 12 alpha-
hydroxy species in serum from DKO and CA fed mice. Fold change values compared to the 




Supplementary Figure 3.3: Transcript profiles in DKO cholestatic livers mimic CAR activated 
livers. 
Venn diagrams quantitate significant similarity in (A) overall, (B) Phase I, and (C) Phase II gene 
changes between DKO and CAR activated livers. Numbers indicate total number of genes in the 
respective livers as well as the overlap of DKO with TC- injected mice (n=3 per group, Fold 




Supplementary Figure 3.4: Loss of FXR mimics only Phase II metabolism in DKO livers. 
Heat maps displaying expression profiles of (A) Phase I and (C) Phase II genes in livers isolated 
from 5 weeks old DKO, FXRKO and SHPKO. Overlap was quantitated in Venn Diagrams (B-
D). Phase I genes are equally distributed between the individual FXRKO and SHPKO, compared 
to DKO livers. However, FXRKO livers show Phase II gene changes similar as DKO livers. No 
overlap between DKO and SHPKO was observed. Numbers indicate total number of genes in the 
respective genotypes as well as overlap of DKO with FXRKO and SHPKO (n=3 per group, Fold 




Supplementary Figure 3.5: Differential expression of genes regulating phase I, II and steroid 
metabolism, and nuclear receptors in biliary atresia patients. 
Biliary atresia microarray data (GEO dataset: GSE46995) was categorized into three cohorts 
based on their GGT levels: low, mid and high. Box plots show relative expression of (A) phase I, 
(B) phase II, (C) nuclear receptors, and (D) steroid metabolic genes. Gene expression was 
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Supplementary Figure 3.6: SHP and detoxification gene profiles do not show significant 
correlations.  
SHP Correlations were compared in the biliary atresia dataset (GSE46995) between low (n= 21) 
and high GGT (n=17) groups. Scatter plots show the extent of correlation between SHP and (A) 
xenosensors: NR1I3 (CAR) and NR1I2 (PXR), (B) phase I genes CYP2C8 and CYP3A4, (C) 
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Supplementary Figure 3.7: Expression profiles of drug metabolic genes in DKO cholestatic mice 
upon acetaminophen-induced toxicity 
(A) qPCR analysis shows upregulation of key genes involved in Phase I and Phase II 
detoxification in DKO livers (n=5 mice per group, Student t test, *p <0.05). (B) Key genes 
responsible for acetaminophen metabolism are suppressed in DKO livers, which may be 























































































Drug	Class: Drug: Enzyme: Induced	by: Reference:
Allergy	Drugs loratadine,	fluticasone Cyp3a4 PXR Yumibe	N	et	al.,	Int	Arch	Allergy	Immunol,	1995.
Steroids estrone,	testosterone Cyp2b6 CAR,	PXR Ohe	T	et	al.,	Drug	Metab	Dispo,	2000,	Imaoka	S	et	al.,	Biochem	Pharmacol,	1996.
Statins lovastatin,	atorvastatin Cyp3a4 PXR Jacobsen	W	et	al.,	Drug	Metab	Dispo,	1999,	Feidt	DM	et	al.,	Drug	Metab	Dispo,	2010.
Proton	Pump	Inhibitors dexlansoprazole,	pantaprazole Cyp2c19,	Cyp3a4 CAR,	PXR Vakily	M	et	al,	Clin	Drug	Investig,	2009.
Anti-diabetics glimepiride Cyp2c9 CAR Niemi	M	et	al.,	Clin	Pharmacol	Ther ,	2001.
glyburide Cyp2c9,	Cyp3a4 CAR,	PXR Niemi	M	et	al.,	Clin	Pharmacol	Ther ,	2001.
Anticoagulants warfarin Cyp2a6,	Cyp2c9 CAR Miles	JS,	et	al.,	Biochem	J,	1990.
phenprocoumon Cyp2a6 CAR,	PXR Miles	JS,	et	al.,	Biochem	J,	1990.
Anesthetics/Analgesics ketamine Cyp2b6 CAR,	PXR Yanagihara	Y	et	al.,	Drug	Metab	Dispo,	2001.
propofol Cyp2b6 CAR,	PXR Oda	Y	et	al.,	Br	J	Clin	Pharmacol,	2001.
fentanyl Cyp3a4 PXR Tateishi	T	et	al.,	Anesth	Analg,	1996.
Antihypertensives irbesartan Cyp2c9 CAR Bourrié	M	et	al.,	Drug	Metab	Dispo,	1999.
losartan Cyp2c9,	Cyp3a4 CAR,	PXR Yasar	U	et	al.,	Drug	Metab	Dispo,	2001.
Infectious	Disease	Drugs artemisinin Cyp2b6 CAR,	PXR Svensson	US	and	Ashton	M,	Br	J	Clin	Pharmacol,	1999.
quinine Cyp2c19,	Cyp3a4 CAR,	PXR Zhao	XJ	et	al.,	J	Pharmacol	Exp	Ther ,	1996.
cyclosporine Cyp3a4 PXR Relling	MV	et	al.,	Mol	Pharmacol,	1994.
Oncological	Drugs tacrolimus Cyp3a4 PXR Shiraga	T	et	al.,	Biochem	Pharmacol,	1994.
lapatinib Cyp2c19,	Cyp3a4 PXR Nelson	MH	and	Dolder	CR,	Ther	Clin	Risk	Manag,	2007.
sorafenib Cyp3a4 PXR Ghassabian	S	et	al.,	Biochem	Pharmacol,	2012.
















Gene Forward Primer (5'-3') Reverse Primer (5'-3') 
36b4 AGATGCAGCAGATCCGCAT GTTCTTGCCCATCAGCACC 
Cyp2b10 TTAGTGGAGGAACTGCGGAAA CGCAAGAACTGACGGTCTG 
Cyp3a11 CAGCTTGGTGCTCCTCTACC CTCTGGGTCTGTGACAGCAA 
Sult2a1 GGAACGAACTGGCTGATTGA AGAGATGGATGGGAAGATGG 
Ugt1a1 ATGGCTTTCTTCTCCGGAAT  TCAGAAAAAGCCCCTATCCC  
Gstm2 TGGAATACACAGACACAAGC CATCAATCAAGTAGGGCAGA 
Gstt3 TATTTCTGTGGCTGACTTGG CACTTCGGCTTCTACTCTCT 
Cyp2e1 TATCTACCTGGAAGCCACAGA GCAGTTGATGTCCAGTGACTTA 
Cyp1a2 CGTCAGCATCCTCTTGCTATT ATGACGTTAGCCACCGATTC 




CHAPTER FOUR: GLOBAL FXR-SHP DELETION INDUCES DYSFUNCTION AND 
METABOLIC REPROGRAMMING IN THE HEART1 
 
4.1. Abstract 
Cardiac dysfunction in patients, secondary to liver cirrhosis, is strongly associated with 
elevated circulating bile acid concentrations. However, the mechanism(s) by which bile acids 
induce cardiomyopathy remain(s) poorly defined. Here we show that bile acid overload 
suppresses fatty acid oxidation (FAO) in cardiomyocytes, resulting in a cardiomyopathy. Fxr-
Shp double knockout (DKO) mice, a model for bile acid accumulation, exhibit cardiac 
hypertrophy, bradycardia, and exercise intolerance. Consistent with this cardiac dysfunction, we 
show that bile acid excess reduces cardiac FAO in vivo and ex vivo and this reduction is Fxr 
independent. Instead, pathological bile acid levels downregulate expression of proliferator-
activated receptor-γ coactivator 1α, a key FAO regulator such that ectopic expression of 
proliferator-activated receptor-γ coactivator 1α in cardiac cells was sufficient to overcome the 
bile acid–mediated reduction in FAO gene expression. Importantly, increased bile acid excretion 
with cholestyramine was able to reverse the observed dysfunction in DKO hearts. In conclusions, 
repressed proliferator-activated receptor-γ coactivator 1α levels drive the metabolic 
reprogramming observed in cirrhotic cardiomyopathy. Moreover, reducing circulating bile acid 
burden can rescue both metabolic and electrophysiological defects in the heart. 
 
4.2. Introduction 
Cirrhotic cardiomyopathy is a cardiovascular comorbidity that is characterized by rhythm 
abnormalities, poor contractility, and incompetence during exercise, catecholamine or 
hemodynamic stress226. More than 50% of patients with end-stage liver diseases exhibit this 
                                                          
1 This work has been published as a paper in: 
Desai M*, Mathur B*, Eblimit Z, Vasquez H, Taegtmeyer H, Karpen S, Penny DJ, Moore DD, 
Anakk S. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart. 
Hepatology 2017 Jan;65(1):189-201. * denotes equal authorship. 
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condition that significantly impedes recovery after surgical procedures, resulting in increased 
fatality227–229. Interestingly, the heart dysfunctions are reversed upon liver transplant230, 
suggesting that this pathology is secondary to liver injury. Despite the wide prevalence and 
clinical significance, no feasible treatment is currently available since he mechanism(s) that 
contributes to its onset and progression remains poorly characterized. Cirrhotic cardiomyopathy 
is a multifactorial disorder associated with a range of pathophysiological manifestations. One 
such factor is elevated serum bile acid levels231. Excess bile acid has been shown to reduce heart 
rate and contractility232,233. Moreover, pathological bile acid levels can promote arrhythmias in 
adults as well as fetuses of mothers with obstetric cholestasis234,235. Despite these strong 
associative findings, how bile acid overload causes heart dysfunction has not been completely 
understood. 
 Typically, a mammalian heart depends on fatty acid oxidation (FAO) for its high-energy 
requirements. However defective cardiomyocyte metabolism can lead to contractile dysfunction, 
progressive left-ventricular remodeling and heart failure236. Additionally, under stress conditions, 
the adult heart undergoes a substrate switch from fatty acid to glucose. Nevertheless, this 
metabolic switch is accompanied by down regulation of the above-mentioned key FAO genes, 
along with an up regulation of key glucose uptake and oxidation genes. This substrate switch 
mirrors the fetal heart and is initially beneficial but eventually leads to heart failure upon 
prolonged stress237,238. Transcriptional control of FAO is regulated mainly by the nuclear 
receptor Proliferator-activated receptor α (PPARα), and its coactivators PGC1α (PPAR-γ 
coactivator 1α)239. Reduced PGC1α level blunts PPARα signaling, resulting in suppression of 
cardiac FAO and ultimately cardiac stress240–242. Whereas, constitutive PGC1α transgenic mice 
demonstrate uncontrolled mitochondrial biogenesis and overt FAO rates, causing heart failure243. 
Therefore, it is critical to maintain appropriate levels of PGC1α in the heart.  
We have found a significant reduction in Pgc1α levels upon bile acid overload. We have 
systematically characterized the effect of bile acids on heart function and physiology using in 
vivo mouse model of bile acid excess and liver injury, ex vivo heart perfusions, as well as in vitro 
primary cardiomyocyte cultures and a cardiac cell line. The severely cholestatic Farnesoid X 
Receptor (Fxr) and Small Heterodimer Partner (Shp) double knockout (DKO) mice110 mimicked 
the key clinical features of cirrhotic cardiomyopathy independent of FXR signaling. Notably, 
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reducing serum bile acid pools in the DKO animals rescued the observed cardiomyopathy. 
Therefore, we conclude that bile acid overload is sufficient to impair myocardial function and 
metabolism. 
 
4.3. Materials and Methods 
Animal models 
Farnesoid X receptor (Fxr) knockout (FXRKO), Small heterodimer partner (Shp) 
knockout (SHPKO) and Fxr-Shp double KO (DKO) mice were generated as described 
previously110. C57BL/6 wild-type (WT) mice were purchased from Envigo/Harlan. Mice were 
housed on a standard 12-hour light/dark cycle and fed normal chow and water ad libitum. To 
reduce circulating bile acid levels, DKO mice were fed a 2% cholestyramine (CHR) diet 
(Envigo) for 5 weeks. All experiments were carried out on 3-5 months old male mice as outlined 
in the Guide for the Care and Use of Laboratory Animals (NIH publication 86-23, revised 1985) 
and approved by the Institutional Animal Care and Use Committee at Baylor College of 
Medicine as well as the University of Illinois at Urbana-Champaign. 
 
Electrocardiograpic and echocardiographic studies 
Mice were sedated (Vevo Digital Scanner; VisualSonic Inc.) prior to recording 
continuous M-mode electrocardiograms using the EC Genie system (Mouse Systems Inc.) as 
described244. Two-dimensional echocardiography was performed in the Mouse Phenotyping Core 
at Baylor College of Medicine and at the Beckman Institute, University of Illinois Urbana-
Champaign (n = 6, age 4-5 months). To determine the acute effect of bile acid excess, WT mice 
were injected intraperitoneally with a single dose of either 100 mg/kg Taurocholic acid or 






Treadmill exercise performance test   
We challenged DKO mice with acute submaximal stress in the form of exercise on a 
treadmill. As previously described, WT and DKO mice (n = 6 per group) were first acclimatized 
on a treadmill for 5-10 minutes and then allowed to run on it at a speed of 2 meters/minute with a 
10% incline. We gradually increased the speed by 2 meters/minute every 2 minutes to a 
maximum of 15 meters/minute. The exercise was stopped when the mouse was sedentary on the 
electric grid at the end of the treadmill for at least two occasions for more than 15 seconds. 
 
Catecholamine challenge and stress echocardiography 
WT and DKO mice (n = 6 per group) were injected intraperitoneally with a single dose of 
20 μg/kg isoprenaline or vehicle (Sigma-Aldrich). Pre and post injection, cardiac parameters 
were evaluated by echocardiography. 
 
Transverse aortic constriction 
WT and DKO mice were subjected to transverse aortic constriction to determine how 
they respond to chronic pressure overload as described previously245. Briefly, mice received 0.6 
mg/kg buprenorphine subcutaneously, followed by isoflurane-induced anesthesia. Between the 
right innominate and left carotid arteries, an incision was made through the ventral chest skin to 
the mid-thorax. A 0.3-mm aortic constriction was placed by tying a 6-0 black-braided non-
absorbable silk suture against a 3-mm length of a 27-gauge needle. 7 days post-surgery, the 
tightness of the constriction was confirmed using a carotid Doppler ultrasound. Cardiac 
contractility was evaluated every 2 weeks by echocardiography for a period of 8 weeks. 
 
Langendorff perfusion experiments 
To evaluate contractility, glucose, and fatty acid (oleate) oxidation rates, the retrograde 
constant flow Langendorff perfusion method was used246,247 on isolated beating DKO and WT 
hearts. In addition, the effect of a high dose of TCA (500 μmol/L) was also evaluated on WT 
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hearts. In brief, the hearts were perfused, and electrophysiological parameters including heart 
rate (cycle beats) and contractility (cycle amplitude) were measured in real time for over 15 
minutes. To quantitate glucose and oleate oxidation rates, the perfusate Krebs-Henseleit buffer (8 
mM glucose, 10 μU/mL insulin, 1.2 mM sodium oleate conjugated to 3% w/v bovine serum 
albumin tracer amounts of [U-14C] glucose [40 μCi/L] and [9,10-3H] oleate [60 μCi/L]) was 
used. After 5 minutes of normal workload perfusion, the hearts were perfused for an additional 
15 minutes under constant flow conditions. Functional and metabolic cardiac parameters were 
measured at 5-minute intervals throughout. 
 
Total serum bile acid levels and composition 
Total serum bile acids were measured using a colorimetric BQ assay kit (BQ Kits, Inc.) 
according to the manufacturer's protocol. Pooled serum from either WT or DKO mice (n = 5-7 
mice) was analyzed for bile acid composition using a liquid chromatographic–mass 
spectrometric method in the Metabolomics Core at Baylor College of Medicine. A Waters 
(Milford, MA) Acquity UPLC BEH C18 column was used for analysis. All bile acids were 
detected in negative mode with l-Zeatine spiked into each sample as an internal standard. 
 
Immunoblotting 
Proteins were extracted from homogenized hearts using standard procedures and their 
concentration was measured using the Pierce BCA kit (Thermo Scientific). After gel 
electrophoresis and transfer, the blots were probed for expression of various proteins with 
specific antibodies, as described244. Equal protein loading was confirmed by TATA binding 
protein (TBP). The results were analyzed by densitometry using Kodak software and are reported 
as fold change compared to WT hearts. 
 
Quantitative real-time polymerase chain reaction 
Total RNA was isolated from snap-frozen hearts (n = 5-6 per group) and cultured HL-1 
cells (n = 4) using TRIzol (Invitrogen, Grand Island, NY). cDNA was prepared from these RNA 
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samples using Maxima reverse transcriptase (Thermo Scientific) and subjected to quantitative 
real-time reverse-transcription PCR using SYBR green (Quanta). The primers are listed in 
Supplementary Table 4.1. Relative RNA expression was calculated by the delta-delta cycle 
threshold method and normalized to 36B4 or 18S as loading controls. 
 
Histology 
Heart tissues from WT and DKO mice (n = 3 each) were fixed in 10% neutral-buffered 
formalin for 24 hours and subsequently processed. 5 μm thick sections were cut, deparaffinized, 
and stained with hematoxylin and eosin as well as Masson's trichrome using standard 
histological protocols. 
 
Quantification of cardiomyocyte size using wheat germ agglutinin staining 
Deparaffinized heart sections (n = 2-3 mice/group) were incubated with 10 μg wheat 
germ agglutinin (WGA)-Alexa Fluor 488 (Thermo Fisher Scientific) for 2 hours at room 
temperature, followed by a couple of washes with 1x phosphate-buffered saline. The slides were 
then incubated with Molecular probe NucBlue (Thermo Fisher Scientific) for 30 minutes at room 
temperature and coverslipped. Eight to ten fields per section per mouse were quantitated using 
ImageJ WGA macro (http://www2.le.ac.uk/colleges/medbiopsych/facilities-and-
services/cbs/lite/aif/software-1/imagej-macros#WGA). 
 
Neonatal mouse cardiomyocyte culture 
Cardiomyocytes were isolated and pooled from 12-15 neonatal WT mouse pups (2-3 days 
old) as described244. Isolated cardiomyocytes (5 × 105 cells/well) were incubated with vehicle 
(dimethyl sulfoxide) or 100 μM chenodeoxycholic acid, CDCA, (Sigma-Aldrich) for 4 hours and 
then were harvested for quantitative real-time PCR analysis. Each experiment was performed in 




Proliferator-activated receptor-γ coactivator 1α overexpression studies 
For Proliferator-activated receptor-γ coactivator 1α (Pgc1α) overexpression, Pgc1α gene 
cloned in a pCDNA3.1 plasmid was obtained as a generous gift from Dr. J.K. Kemper's 
laboratory at University of Illinois, Urbana-Champaign. The cardiac HL-1 cell line was cultured 
as described248. Approximately 80% confluent HL-1 cells were transfected with 50 ng of the 
Pgc1α plasmid or empty vector using TransIT 2020 reagent (Mirus Bio) for 24 hours, followed 
by CDCA (100 μM) or Vehicle (dimethyl sulfoxide) treatments. After 4 hours of CDCA 
incubations, cells were harvested for gene profiling using quantitative real-time PCR assays. 
 
Statistical analysis 
Data are presented as mean ± standard error of the mean using GraphPad Prism. Data 
between two groups (DKO or FXRKO or SHPKO and WT) were compared using the unpaired t 
test as well as the nonparametric Mann-Whitney, as mentioned in the respective figure legends. 
Preintervention and postintervention WT or DKO and DKO+CHR comparisons were performed 
using one-way analysis of variance, followed by Bonferroni post hoc test unless specified. Pgc1α 
overexpression analyses were evaluated using multiple t tests and two-way analysis of variance, 
followed by a Bonferroni post hoc test. Ex vivo and in vitro experiments were performed using 
the nonparametric Mann-Whitney test. P < 0.05 was selected as the level of significance. 
 
4.4. Results 
We utilized DKO mice in which two key nuclear receptors Fxr and Shp, responsible for 
maintaining bile acid levels, are globally deleted110. DKO mice display severe hepatotoxicity as 
marked by increases in alanine aminotransferase and aspartate aminotransferase liver enzymes 
and bile acids overload, thereby making them are an excellent model of liver disease 





DKO mice exhibit hallmarks of Cirrhotic cardiomyopathy  
Compared to adult WT mice, DKO mice had enlarged hearts marked by significantly 
higher heart weight to tibial length ratio (Figure. 4.1A). This was due to the increased 
cardiomyocyte size in DKO hearts as observed by WGA staining of the cell membrane (Figure 
4.1B). Consistent with the cellular hypertrophy, the core cytoskeletal proteins α/β actin and α/β 
tubulin249 were induced in DKO hearts (Figure 4.1C). However, DKO hearts did not show any 
signs of injury or fibrosis upon hematoxylin and eosin as well as Masson's trichrome staining 
respectively (Supplementary Figure 4.1C, D). Two-dimensional echocardiograph of DKO hearts 
demonstrated abnormality on M-mode as well as decreased left ventricular internal diameter 
(LVID) in diastole and systole (Figure 4.1D). Cardiac output of DKO mice was lower than WT 
mice, despite compensatory increases in LV shortening and ejection fraction (Figure 4.1E). 
Furthermore, DKO hearts displayed extended QTc and PR intervals on echocardiography (Figure 
4.1E), which is strongly correlated with the observed mortality in patients with Cirrhotic 
cardiomyopathy250,251. Additionally, DKO hearts showed bradycardia, along with induction of 
myosin heavy chain β isoform (β-MyH7), AKT (Phospho-Ser473) and c-Jun N-terminal kinase 
(Phospho-Thr183/Tyr185), and apoptotic pathways (Supplementary Figure 4.2), all of which are 
molecular signature of pathological cardiac remodeling252. Finally, we observed a significant 
elevation in serum cardiac troponin-2 levels (Figure 4.1F) in DKO mice, indicating myocardial 
injury253. Together, these data clearly suggest that DKO mice mimic clinical symptoms of 
Cirrhotic cardiomyopathy. 
 
DKO mice demonstrate weakened response to exogenous cardiac stressors 
Patients with cirrhotic cardiomyopathy have impaired response to exercise-induced 
stress254 and catecholamines230. When challenged with acute exercise stress, DKO mice 
performed poorly in terms of both the distance run and the respective time taken on the treadmill 
compared to WT mice (Figure 4.2A, B). Further, DKO mice took twice the amount of time to 
achieve the peak increase in heart rate than the controls upon isoprenaline challenge (Figure 
4.2C). Moreover, this peak heart rate was modestly lower in the DKO mice (Figure 4.2D) along 
with diminished ejection fraction (Figure 4.2E). The increase in shortening fraction in the DKO 
mice pre–isoprenaline treatment was blunted post injection, suggesting repressed β-adrenergic 
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signaling (Figure 4.2F). Finally, we investigated if DKO hearts can handle pressure overload by 
performing transverse aortic constriction. Though the decrease in shortening fraction was 
comparable between DKO and WT mice in response to transverse aortic constriction, we found a 
modest but significant decrease in ejection fraction and an increase in heart weight the DKO 
mice (Supplementary Figure 4.2E, F). 
 
DKO hearts undergo a switch to the fetal metabolic gene program 
The metabolic substrate switch from fat to glucose in a stressed heart encompasses 
reactivation of the fetal gene network255. We observed downregulation of the key FAO 
regulators, Pgc1α and peroxisome proliferator–activated receptor alpha (Pparα) (Figure 4.3A; 
Supplementary Figure 4.3A). Corroboratively, a panel of PGC1α target genes, including 
mitochondrial carnitine palmitoyl transferase-1/2 (mCpt1/2); estrogen-related receptor 
alpha/gamma (Errα/γ); mitochondrial transcription factor (Tfam), nuclear respiratory factor-1 
and 2 (Nrf-1/2) (Figure 4.3B, C; Supplementary Figure 4.3) were robustly reduced in DKO 
hearts. Additionally, DKO hearts displayed suppression of a known inhibitor of glucose 
oxidation, pyruvate dehydrogenase kinase 4 (Pdk4) (Figure 4.3D). These data indicate that DKO 
hearts switch from FAO to glucose metabolism, indicating cardiac stress. 
To examine if these altered gene profiles functionally reflect a metabolic switch in DKO 
hearts, we measured the rate of FAO and glucose oxidation using ex vivo Langendorff heart 
perfusions. DKO hearts displayed a reduction in oleate oxidation with a subsequent increase in 
glucose oxidation within 15 minutes (Figure 4.3E, F), thereby concluding that the blunted 
function in DKO hearts is linked to its metabolic reprogramming. 
 
Individual loss of Shp, but not Fxr, may contribute to cardiac pathology in DKO mice  
Roles for FXR in myocardial injury256 and SHP in cardiac hypertrophy257 have been 
recently discovered. Therefore, we examined if individual ablation of Fxr (FXRKO) or Shp 
(SHPKO) can cause the metabolic defect in DKO mice. FXRKO hearts demonstarted no 
decreases in the expression of metabolic genes including Pgc1α, Pparα, and their downstream 
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targets. Instead, Pparα, m-Cpt2, and Pdk4 were induced in FXRKO mice (Supplementary Figure 
4.4A-E). In line with this finding, the echocardiograph showed no abnormalities in heart rate and 
contractility in FXRKO hearts, compared to WT counterparts (Supplementary Figure 4.4F). On 
the contrary, SHPKO hearts exhibited a modest downregulation of m-Cpt1 and Pdk4 expression 
(Supplementary Figure 4.5A-E). Moreover, the echocardiographic findings displayed no 
abnormality in contractility, but slightly reduced heart rate in SHPKO mice compared to their 
WT littermates (Supplementary Figure 4.5F).  
 
Bile acids are sufficient to drive the dysfunction in DKO hearts 
To specifically characterize the effect of acute bile acid overload on the heart, we injected 
WT mice with either bile acid TCA, LCA or vehicle and performed pre-injection and post-
injection electrocardiography and echocardiography. Bile acid injections significantly suppressed 
heart rate and modestly reduced LV diameter in naive WT mice (Supplementary Figure 4.6A, 
B), but did not change other echocardiographic parameters (Supplementary Figure 4.6C). 
Subsequently, we investigated if acute bile acid burden can promote the metabolic switch 
in the heart using the Langendorff method. TCA perfusion of WT hearts resulted in a rapid 
decrease in the heart rate and cycle amplitude (an indicator of myocardial contractility) 
(Supplementary Figure 4.6D, E). Moreover, oleate oxidation was dramatically reduced by 50% 
within 15 minutes (Supplementary Figure 4.6F). Overall, these data signify that bile acid excess 
is sufficient to induce metabolic and functional defects in the heart. 
To identify how bile acids drive metabolic reprogramming, we utilized in vitro primary 
cardiomyocyte cultures as well as the well-studied cardiac HL-1 cell line248. Cardiomyocytes 
were treated with the pathological CDCA concentration observed during liver diseases258. 
Remarkably, CDCA dramatically suppressed not only the FAO regulators such as Pgc1α, m-
Cpt1, Nrf-1, Nrf-2, and Tfam (Figure 4.4A-D), but also the glucose oxidation inhibitor Pdk4 
(Figure 4.4E) in primary cardiomyocytes. However, no changes in m-Cpt2 (Figure 4.4B) levels 
were observed in response to CDCA. Similar gene alterations were observed in HL1 cardiac 
cells when challenged with high doses of CDCA (Figure 4.5). However, a physiological dose of 
CDCA failed to induce any alterations in the metabolic gene profiles (data not shown). 
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Importantly, the metabolic changes observed in primary cardiomyocytes and HL-1 cells upon 
bile acid incubations mimicked the DKO mice hearts (Figures 4.3-4.5). 
 
Ectopic expression of Pgc1α rescues bile acid–mediated metabolic defects in vitro 
Hearts from Pgc1α KO mice exhibit increased glucose oxidation and decreased FAO, 
indicating that Pgc1α is the master regulator for cardiac metabolism242,259,260. Therefore, we 
determined if the metabolic defects induced bile acids can be reversed by Pgc1α overexpression 
in HL-1 cells. 50-fold Pgc1α levels were obtained in HL-1 cells, which was maintained even 
upon CDCA treatment (Figure 4.5A). CDCA-mediated reductions in FAO genes Pparα and m-
Cpt1 and glucose oxidation gene Pdk4 were reversed upon this Pgc1α overexpression, 
highlighting that the observed substrate switch is dependent on bile acid-induced down-
regulation of Pgc1α (Figure 4.5B-D). 
 
Reducing bile acid burden in the serum completely reversed cirrhotic cardiomyopathy in DKO 
mice 
To determine if pathological bile acids were directly responsible for the observed cardiac 
defects, DKO mice were fed a bile acid sequestering resin, known to decrease circulating bile 
acid levels, Cholestyramine (CHR). As expected, the serum bile acid concentrations were 
reduced to half in DKO mice fed CHR diet. This reduction is also concurrent with the overall 
decrease in bile acid composition (Figure 4.6A). 
M-mode echocardiograph displayed that CHR feeding in the DKO mice restored 
electrophysiological parameters, including heart rate, cardiac output, LVID in both diastole and 
systole to WT levels (Figure 4.6B, C). In line with these data, FAO genes Pgc1α, m-Cpt1, and m-
Cpt2 were up-regulated in CHR fed DKO hearts, compared to Chow fed DKO hearts (Figure 
4.6D, E). Overall, these findings strongly indicate that decreasing serum bile acid pools are 
sufficient to rescue cardiac pathology associated with liver diseases. A schematic of the overall 





Heart dysfunction can be caused by a wide range of end-stage liver disorders, like 
alcoholic cirrhosis, chronic hepatitis B or C viral infection and nonalcoholic fatty liver 
disease226,229,261–263. However, the mechanisms underlying this liver disease–driven heart failure 
are not completely elucidated. Liver dysfunction is always accompanied by increased circulating 
pool of bile acids264, which are known to be associated with cardiomyopathy231–233,264. For 
instance, jaundice and/or cholestasis can inhibit β-adrenergic signaling, thereby resulting in 
reduced cardiac contractility in these patients261. In this chapter, we define a novel mechanism by 
which the pathological bile acid levels cause dysfunction and metabolic switch in the heart. This 
project, combined with in vitro studies previously conducted, further strengthen the role of bile 
acid-myocardial interaction in cirrhotic cardiomyopathy and highlight the cardio-toxic potential 
of bile acids. 
The Fxr-Shp DKO mouse is an excellent model to study Cirrhotic cardiomyopathy since 
it displays severe liver injury along with elevated circulating bile acids and hepatic enzymes 
alanine aminotransferase and aspartate aminotransferase. Moreover, DKO mice do not exhibit 
acute pharmacologic and toxicologic confounding factors compared to 3,5-diethoxycarbonyl-1,4-
dihydrocollidine and carbon tetrachloride toxic models of end stage liver disease265,266. However, 
the limitation of using DKO model is that it is a global knockout instead of a cardiomyocyte-
specific one. To address this concern, we performed ex vivo and in vitro bile acid treatments in 
WT cells that have intact expression of Fxr and Shp in cardiomyocytes. This allowed us to define 
the bile acid-myocardial interactions, independent of Fxr-Shp signaling.  
Hearts of patients with end-stage liver diseases exhibit tachycardia, hypertrophic LV with 
diastolic dysfunction, prolonged QT interval, and poor response to exercise and catecholamine-
induced stress. DKO mouse hearts phenocopied all these features of cirrhotic cardiomyopathy, 
except for tachycardia. Instead, DKO hearts display bradycardia. This could be due to increased 
bile acid levels since they have been known to inhibit heart rate232,267. Additionally, cytoskeletal 
proteins as well as c-Jun kinase and AKT pathways were induced, suggesting molecular 
remodeling in DKO cardiomyocytes. 
Cardiac function has been known to be dependent on its metabolic capacity. Contractile 
dysfunction, progressive LV remodeling, and heart failure are preceded by perturbations in 
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cardiac metabolism243,260. Consistently, DKO hearts demonstrated suppression of key regulators 
of FAO (Pgc1α, Pparα), along with decreased expression of FAO target genes (m-Cpt1, m-
Cpt2). Moreover, this was accompanied by suppression of PDK4, a negative regulator of glucose 
oxidation. Changes at the molecular level were substantiated by changes in myocardial 
metabolism at the level of the whole heart. In ex vivo preparations, DKO hearts showed a 
decrease in FAO, followed by a concomitant increase in glucose oxidation. Taken together, these 
results indicate a switch from fatty acid to glucose as a source of energy for myocardial 
contractility – a hallmark of myocardial adaptation to stress (Fig.2C). This adaptation probably 
gets overwhelmed in situations of stress, leading to catecholamine resistance and exercise 
intolerance seen in the DKO mice. 
Elevated bile acid pools are toxic to the heart235,258,264, especially TCA is known to induce 
fetal arrhythmias, cardiac stress and poor contractility233,234,268. Interestingly, bile acids are 
evolving as signaling molecules101,269 that regulate metabolism and function in various tissues. 
They signal via nuclear receptor FXR as well as membrane receptor TGR5, both of which are 
present in cardiomyocytes244. We examined whether the loss of FXR or SHP contributes to 
cardiac dysfunction in DKO mice. Activation of FXR is known to promote vasodilation270,271, 
whereas its deletion protects against apoptosis in the heart256. We observed that FXRKO mice 
exhibit normal cardiac function metabolism. Therefore, FXR ablation does not cause pathology 
in DKO hearts. However, deletion of SHP resulted in bradycardia, accompanied by a few 
alterations in metabolic gene profiles that were comparable to DKO mice. This finding 
corroborated with the recently identified function for SHP as a hypertrophic repressor in the 
heart257. However, to fully define the role for FXR and/or SHP in the heart, cardiomyocyte-
specific Fxr and Shp single and double knockouts would be necessary to characterize. 
Additionally, it is possible that the other bile acid receptor TGR5272 could drive these metabolic 
and physiological responses in the heart. To address this possibility, further studies will be 
needed to identify the potential function of TGR5 in cardiomyopathy. 
Additionally, when WT hearts were subjected to high dose of bile acid, we observed 
bradycardia along with a significant downregulation of FAO within 15 minutes. Moreover, bile 
acid incubation of primary cardiomyocytes repressed key FAO genes. These findings together 
signify how metabolic reprogramming can impact cardiac function upon bile acid excess 
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independent of FXR or SHP function. Instead, this observed metabolic switch upon bile acid 
challenge was rescued by overexpression of Pgc1α, suggesting that bile acid mediated Pgc1α 
down-regulation is crucial to alter cardiac metabolism.  
Finally, we identified that decreasing bile acid burden in the circulation with bile acid 




Our findings define a direct role for pathological bile acid concentrations in altering 
cardiac metabolism in a Pgc1α dependent manner. Importantly, reducing circulatory bile acid 
pools by promoting their excretion via CHR rescued cardiomyopathy observed in DKO mice. 
This allows us to utilize this clinical pre-approved bile acid resin as a potential therapeutic to 












4.7. Figures and legends 
 
Figure 4.1: DKO mice show cardiac hypertrophy and abnormal cardiovascular parameters. 
 (A) Compared to WT, DKO mice exhibited increased heart weight to tibial length ratio. (B) 
DKO cardiomyocytes were larger as quantified by WGA staining (n=2-3 mice per group, ***p < 
0.001). (C) Cardiac cytoskeletal proteins -actin and -tubulin were induced in DKO hearts as 
seen by western blots. TATA binding protein was used as the loading control. (D) M-mode 
echocardiographic images of the LV displayed reduction in LVID in both diastole and systole in 
DKO mice. (E) Ejection fraction, shortening fraction, and QTc and PR intervals were increased 
in DKO mice, whereas cardiac output was reduced. (F) Enzyme-linked immunosorbent assay for 
cardiac troponin T showed induction in DKO mice (n=6-12 mice/group; *p < 0.05, ** p < 0.001 
compared to WT mice, mean ± standard error of mean). Abbreviations: CO, cardiac output; EF, 
ejection fraction; FS, shortening fraction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; 




Figure 4.2: DKO mice demonstrate exercise intolerance and catecholamine insensitivity.  
WT mice were able to run a greater distance (meters) (A) and for a longer time (minutes) on the 
treadmill (B) compared to DKO mice. Upon isoprenaline challenge, DKO mice took longer to 
reach peak heart rate (C, D) and displayed lower changes in ejection fraction and shortening 
fraction (E, F). (n=5-6/group; *p < 0.05, **p < 0.01 compared to WT animals, mean ± standard 



















































































































Figure 4.3: Metabolic switch occurs in DKO hearts.  
Compared to WT, quantitative RT-PCR analysis of DKO hearts revealed significant down-
regulation of FAO genes Pgc1a and m-Cpt1/2 (A-C). Additionally, the regulator of glucose 
oxidation, Pdk4 was altered in DKO hearts (D). All gene expression data were normalized to 
36b4. (E, F) Line diagram showed a switch from oleate to glucose oxidation in the DKO whole 
hearts mounted ex vivo on the Langendorff apparatus (n=5/group; *p < 0.05, **p < 0.01, ****p 





































































Figure 4.4: Bile acids are sufficient to suppress FAO genes in primary cardiomyocytes.  
Neonatal cardiomyocytes, incubated with CDCA (100 μM) for 4 hours, were evaluated for key 
genes regulating fatty acid and glucose oxidation. 18s was used as the loading control. Values 







































































Figure 4.5: Overexpression of Pgc1a is sufficient to reverse bile acid–mediated alteration in 
metabolic genes.  
Pgc1a was ectopically expressed in a cohort of HL-1 cells prior to CDCA treatments. The 
CDCA-mediated switch in metabolic genes in vitro was effectively rescued by Pgc1a 
overexpression. Gene expression was normalized to 36b4 (n=4-6; *p < 0.05 compared to vehicle, 
#p <0.05, ##p < 0.01 compared to CDCA-treated HL-1 cells, mean ± standard error of mean). 



























































Figure 4.6: Reduction in circulating bile acid pools reverts the observed cardiomyopathy in vivo. 
(A) DKO mice fed CHR exhibited a 50% decrease in serum bie acid levels compared to DKO 
mice on chow. Serum bile acid composition is shown as fold change to WT mice. (B) Two-
dimensional echocardiographic analysis revealed normal heart rate and cardiac output in CHR-
fed DKO mice. (C) LVID in diastole and systole was restored to the WT level when DKO mice 
were fed CHR. (D, E) The fatty acid regulator Pgc1a and metabolic genes (m-Cpt1/2) were 
upregulated in DKO+CHR hearts compared to DKO+chow mice. Gene expression was  
99 
 
Figure 4.6 (Con’t.)  
normalized to 36b4 (n=4-7 mice/group; *p < 0.05, **p < 0.01, ****p < 0.001 compared to WT 
chow; #p < 0.05, ##p < 0.01, ###p < 0.005 compared to DKO chow; mean ± standard error of 
mean). (F) Proposed schematic indicating a mechanism by which bile acid overload can induce a 
metabolic switch in the heart, resulting in cardiac hypertrophy and dysfunction. Abbreviations: 
BA, bile acid; CA, cholic acid; DHCA, 3α, 7α-dihydroxycholestanoic acid; GHCA, 
glycohyocholic acid; GLCA, glycolithocholic acid; HCA, hyocholic acid; HDCA, 
hyodeoxycholic acid; LCA, lithocholic acid; MCA, muricholic acid; TCDCA, 
taurochenodeoxycholic acid; THDCA, taurohyodeoxycholic acid; TMDCA, 













4.8. Supplementary Figures, Table and Legends 
 
Supplementary Figure 4.1: DKO mice accumulate excess bile acids and demonstrate liver 
damage but exhibit no fibrosis or overt injury in the heart. 
(A) Serum bile acid levels were dramatically elevated in DKO compared to the individual 
FXRKO and SHPKO mice. (B) Serum ALT and AST levels were also increased in DKO mice 
than the WT controls. This data is in line with our previous findings. (n=5-6 mice/group; ** 
p<0.01 compared to WT mice; Mean ± SEM). Heart tissues from WT and DKO mice were 
processed, sectioned and stained with Hematoxylin & Eosin (C), and Masson’s trichrome (D) to 




Supplementary Figure 4.2: DKO hearts exhibit hypertrophy, bradycardia, distress and poor 
response to pressure overload. 
(A) DKO hearts show increased heart-to-body weight ratio, which is corroborated by induced 
expression of cytoskeleton gene β-MyH7 (B). DKO hearts exhibit reduced heart rate (C), along 
with activation of stress as well as pro-apoptotic pathways (D). Upon TAC, DKO mice displayed 
an increase in heart weight and decrease in ejection fraction (EF) with modest decrease in 
shortening fraction (FS) in comparison to WT mice (E-F) (n=5-6/group; *p<0.05, **p<0.01 













































































Supplementary Figure 4.3: Pgc1α downstream signaling is repressed in DKO hearts. 
qRT-PCR analysis was performed on the RNA isolated from 5 months old WT and DKO hearts 
for Pgc1α downstream target genes (A-D). The expression levels were normalized to 36b4. (n=4-














































































Supplementary Figure 4.4: Deletion of FXR does not alter electrophysiological parameters of 
the heart but induces FAO and inhibits glucose oxidation.  
qRT-PCR analysis was performed on the RNA isolated from 5 months old WT, and FXRKO 
hearts for the genes regulating fatty acid oxidation and glucose utilization (A-E). The expression 
levels were normalized to 36b4. FXRKO mice showed normal cardiovascular parameters as 
evaluated by echocardiography (F) compared to WT controls. (n=3-6 mice/ group; *p<0.05; 






























































































Supplementary Figure 4.5: Deletion of SHP reduces heart rate, mCpt1 but increases glucose 
oxidation.  
qRT-PCR analysis was performed on RNA isolated from WT and SHPKO hearts for the genes 
regulating fatty acid oxidation and glucose utilization (A-E). The expression levels are 
normalized to 36b4. SHPKO mice showed normal cardiovascular parameters, except for a 
decrease in heart rate (F) compared to WT controls. (n=3-6 mice/ group; *p<0.05; **p<0.01 
when compared to WT mice; Mean± SEM). 






























































































Supplementary Figure 4.6: Exogenous administration of bile acids induces bradycardia and 
metabolic reprogramming in the hearts.  
WT mice were injected with 100 mg/kg Lithocholic Acid (LCA) or corn oil vehicle for 4 days (1 
dose/day). (A-B) Bar graph show significant reduction in heart rate and left ventricular inner 
diameter. (C) However, the acute exposure to bile acids in vivo was not sufficient to alter 
ejection fraction or shortening fraction. (D-F) WT mice injected with 100mg/kg Taurocholic 
Acid (TCA) demonstrated bradycardia, decreased cycle amplitude and oleate oxidation, 
compared to the mice injected with corn oil. (n=3-4 mice/group; *p<0.05; **p<0.01 when 









































































Gene Forward Primer Reverse Primer
Troponin, cardiac 5’- TCTGCCAACTACCGAGCCTAT-3’ 5’- CTCTTCTGCCTCTCGTTCCAT -3’
Pgc1a 5’- CCCACAGAAAACAGGAACAG -3’ 5’- CTGGGGTCAGAGGAAGAGAT -3’
Ppara 5’- ACAAGGCCTCAGGGTACCA -3’ 5’- GCCGAAAGAAGCCCTTACAG -3’
m-Cpt 1 5’- GCGACAGGCATTTTCTTC -3’ 5’- AGGAGACGGACACAGATAGC -3’
m-Cpt 2 5’- GCTGCCTATCCCTAAACTTG -3’ 5’- CTTCCCAATGCCGTTCTC -3’
Erra 5’- GTACGTCCTGCTGAAAGCTC -3’ 5’- CCAGCTTCATACTCCAGCAG -3’ 
Errg 5’- GTTGTGTACCGATCGCTTTC -3’ 5’- CCAGCTGCAGGATAGCATTA -3’
Pdk4 5’- GGATTACTGACCGCCTCTTTAGT -3’ 5’- AGATGATAGCGTCTGTCCCATAA -3’
Nrf-1 5’-  GCACCTTTGGAGAATGTGGT -3’ 5’- CTGAGCCTGGGTCATTTTGT -3’
Nrf-2 5’-  CTCTCTGAACTCCTGGACGG -3’ 5’- GGGTCTCCGTAAATGGAAG -3’
Tfam 5’-  CAAGTCAGCTGATGGGTATGG -3’ 5’- TTTCCCTGAGCCGAATCATCC -3’
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CHAPTER FIVE: FUTURE DIRECTIONS AND CONCLUSIONS 
In conclusion, we have identified non-canonical roles for nuclear receptors FXR and SHP in 
liver physiology, diseases and beyond. In addition to their role as transcriptional regulator, FXR-
SHP can modulate the spatial distribution of cholesterol in a hepatocyte, thereby altering the 
structure and function of an organelle, Golgi apparatus. Not only this, FXR-SHP axis also play 
an important role in maintaining protein glycosylation such that loss of this axis results in 
hyperbranching and increased complexity of glycan decorations on liver proteins. These glycan 
decorations regulate functions of several proteins in cellular signaling and adhesion, and 
increased glycan complexity is known to be associated with cancer. These findings highlight a 
possible mechanism by which hepatic ablation of FXR-SHP causes liver tumorigenesis. Further, 
global loss of FXR-SHP axis is known to cause cholestasis (bile acid accumulation). We have 
found that these cholestatic mice show increased drug metabolic capacity, which is attributed to 
activation of hepatic xenosensing nuclear receptor CAR. These findings were also recapitulated 
in patients suffering from biliary atresia, a type of cholestasis, indicating the importance to target 
the cross talk between FXR-SHP-CAR to treat cholestasis. In addition, these findings are of 
direct clinical relevance. Since most drugs are metabolized by CAR, it is crucial to monitor the 
hepatic detoxification ability of a patients and adjust the drug dosage accordingly. Not only the 
liver, but loss of FXR-SHP signaling can also induce cardiomyopathy via circulating bile acid 
pools. We demonstrated that bile acid excess induces a metabolic switch from fat to glucose in 
cardiomyocytes. This leads to lower ATP generation to meet the cardiac demand, resulting in 
lower heart rate and cardiac output. Interestingly, reducing bile acid levels using an FDA 
approved drug reversed this diseased cardiac phenotype. This drug could be used in clinics to 
target patients suffering from cardiomyopathy secondary to liver dysfunction. Overall, these 
findings highlight the important of FXR-SHP networks in maintaining cellular functions since 
perturbing these signals can cause cholestasis, liver cancer and heart diseases. 






Chapter Two  
 This chapter identifies a novel role for hepatic Fxr-Shp signaling in regulating protein 
glycosylation and Golgi dynamics.  
How does Fxr and/or Shp regulate cholesterol accumulation in Golgi and if this accumulation is 
sufficient to cause the glycosylation defect? 
 We observe accumulation of cholesterol in Golgi and secretory vesicles in LDKO livers. 
It will be crucial to identify how and why does this occur? What are the molecular mechanisms 
that control cholesterol trafficking in LDKO mice. Does FXR-SHP transcriptionally regulate this 
process? Further, proving if cholesterol accumulation is sufficient to cause this Golgi structural 
and functional defect in secretomics and glycosylation will be of utmost importance in the field. 
If not, what could be the other mechanisms underlying this defect. Cellular division and pH level 
of the Golgi apparatus in known to regulate its dynamics. It would be interesting to study if these 
are changed in LDKO livers. 
 
Does glycosylation defect in LDKOs prime the liver for tumorigenesis? 
 Our data and Ho K. et al demonstrated that LDKO livers develop HCC273. However, the 
tumor volume is significantly lower than the DKOs. Since deletion of hepatic Fxr-Shp 
contributed only modestly to the tumor phenotype, our lab has developed intestinal Fxr-Shp 
double knockout (IDKO) mice which were aged and found to not develop HCC. This indicated 
that presence of hepatic Fxr-Shp axis maybe crucial to protect against HCC. It will be interesting 
to determine if LDKO mice get tumor because of altered function of proteins, due to their glycan 
hyperbranching. Glycan hyperbranching in proteins can alter their interactions with proteins in 
the ECM or a neighboring cell146–148. We will first perform glycoproteomics on key cell adhesion 
glycoproteins in LDKOs as well as single Fxr or Shp knockouts. This analysis will determine the 
role of Fxr and/or Shp in regulating cell adhesion. Next, we could culture primary hepatocytes 
from control, individual and double Fxr-Shp knockouts using hydrogels and measure the cell-
ECM traction as well as cell-cell tension. The Mgat5 and Fut8 activity in LDKO can be inhibited 




Can FXR agonist be beneficial in patients suffering from N-glycosylation defects? 
 Overexpression of Mgat5 can result in increased metastasis potential of cancerous 
cells146,147,185,274–278. We have shown that FXR activation can repress Mgat5 transcription. Our 
lab would determine if FXR individually can regulate MGAT5 activity. If this is true, clinically 
approved FXR agonist INT-747279,280 could be tested in patients to suppress metastasis of Mgat5-
positive cancers.  
 
Can combined ablation of hepatic Fxr and Shp alter glucose flux distribution? 
Glucose can either be broken down by glycolysis, stored as glycogen or directed into 
HBP pathway178,179. LDKO mice has lower circulating glucose, increased glycosylation, no 
alterations in glycolytic genes and drastically lower hepatic glycogen content. We will quantitate 
the levels of HBP intermediates to determine if glucose is being siphoned into HBP pathway to 
meet the increased glycosylation demands. 
 
Chapter 3 
This chapter focuses on studying detoxification ability of the liver, subsequent to cholestasis 
caused by loss of Fxr-Shp signaling.  
Does cholestasis result in changes in the localization of drug metabolic enzymes in the liver? 
It is known that during liver dysfunction (as in biliary atresia), the livers undergo 
regeneration. In this case, the hepatocytes may transdifferentiate into ductal cells and vice versa. 
It will be interesting to perform an immunofluorescence staining on these livers to determine the 
where these detoxification enzymes are present in various cholestatic conditions. Further study 
on what causes this transdifferentiation will further help understand this process. Does FXR-SHP 






Examine the role of ploidy in the cholestasis? 
Since polyploid hepatocytes are known to show increased drug metabolism, it will be 
crucial to determine if the ploidy status of the cholestatic hepatocytes change? Do they exhibit 
higher or lower ploidy? Could we establish a correlation between the ploidy state and the extent 
of cholestasis in the livers? Does FXR-SHP axis regulate hepatocellular ploidy? 
 
Chapter 4 
Here we discussed how bile acid excess, due to Fxr-Shp ablation, can cause cardiomyopathy. 
How does Bile acid regulate Pgc1α levels? 
 We have shown that pathological BA concentrations repress Pgc1α in hearts. But the 
mechanism underlying this BA-mediated suppression of Pgc1α is not yet characterized. 
Phospho-AKT, a signaling kinase, and Myocyte-specific enhancer factor 2c (Mef2c), a 
transcriptional regulator, are known to mediate BA effects in the heart. Further, AKT 
overexpression is known to result in a 3-fold decrease in Pgc1α levels and activity281. Secondly, 
MEF2C activation and its binding to the Pgc1α promoter is necessary to induce Pgc1α 
transcription. DKO mice demonstrates activation of AKT signaling as well as in vitro BA 
incubation results in down regulation of Mef2c. Test these two potential mechanisms by 
silencing the AKT pathway and/or overexpressing Mef2c in primary cardiomyocytes, and in vivo 
and examine their cardiac function in the presence or absence of BAs. In addition, determine 
how BA signal to the cardiomyocyte by characterizing BA-Tgr5 signaling. 
 
Can Cholestyramine be used to cure Cirrhotic cardiomyopathy in clinics? 
 We have identified that Cholestyramine feeding reverts the observed cardiac pathology in 
DKO mice. Cholestyramine fed DKO hearts not only show normal electrophysiological 
parameters including heart rate, cardiac output, but also prefer fat as their metabolic substrate. 
This FDA approved drug282,283 could undergo clinical trials and be utilized as a therapeutic to 
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